ELSEVIER

International Journal of Pharmaceutics 112 (1994) 267–289

international journal of pharmaceutics

Author Index Vol. 101–112

Abdelnasser, M.A., see Desai, D.S. (103) 69

Aboofazeli, R. and Lawrence, M.J.
Investigations into the formation and characterization of phospholipid microemulsions. II. Pseudo-ternary phase diagrams of systems containing water-lecithin-isopropyl myristate and alcohol: influence of purity of lecithin (106) 51

Aboofazeli, R., Lawrence, C.B., Wicks, S.R. and Lawrence, M.J.
Investigations into the formation and characterization of phospholipid microemulsions. III. Pseudo-ternary phase diagrams of systems containing water-lecithin-isopropyl myristate and either an alkanoic acid, amine, alkanediol, polyethylene glycol alkyl ether or alcohol as cosurfactant (111) 63

Acree, Jr, W.E. and Tucker, S.A.
Thermochemical investigations of associated solutions: 16. Comparison of the extended NIBS model and mobile order theory for solubility in systems containing solute-solvent complexation (101) 199

Adjei, A., Hui, J., Finley, R., Lin, T., Lancaster, J. and Fort, F.
Pulmonary bioavailability of leuprolide acetate following multiple dosing to beagle dogs: some pharmacokinetic and preclinical issues (107) 57

Adjei, A., see Powers, M.E. (108) 49

Agbada, C.O. and York, P.
Dehydration of theophylline monohydrate powder – effects of particle size and sample weight (106) 33

Ah-Fat, N.M.W., Craig, D.Q.M. and Taylor, K.M.G.
An investigation into the effects of surfactants on phospholipid monolayers using a Langmuir-Blodgett film balance (107) 239

Ahlbom, J., see Gottfries, J. (106) 141

Ahlneck, C., see Elamin, A.A. (108) 213

Ahlneck, C., see Elamin, A.A. (111) 159

Ahlneck, C., see Saleki-Gerhardt, A. (101) 237

Ahlneck, C., see Sebhatu, T. (104) 135

Ahmed, S.M., Casu, B., Cedro, A., Guerrini, M., Lanzarotti, E., Moltrasio, D., Naggi, A. and Torri, G.
Disruption of micellar aggregates of ganglioside GM-1 by complexation with α-cyclodextrin (109) 99

Akbuğa, J. and Durmaz, G.
Preparation and evaluation of cross-linked chitosan microspheres containing furosemide (111) 217

Akın, A., see Şener, E. (110) 109

Al-Angary, A.A., see El-Sayed, Y.M. (109) 107

Al-Angary, A.A., see Hosny, E.A. (112) 87

Al-Balla, S.R., see El-Sayed, Y.M. (109) 107

Al-Meshal, M.A., see El-Sayed, Y.M. (109) 107

Al-Meshal, M.A., see Hosny, E.A. (112) 87

Alard, V., see Zeevi, A. (108) 57

Aldén, M., Lydén, M. and Tegenfeldt, J.
Effect of counterions on the interactions in solid dispersions between polyethylene glycol, griseofulvin and alkali dodecyl sulphates (110) 267

Alderborn, G., see Ek, R. (111) 43

Alderborn, G., see Elamin, A.A. (108) 213

Alderborn, G., see Elamin, A.A. (111) 159

Alderborn, G., see Eriksson, M. (109) 59

Alhaique, F., see Touitou, E. (103) 131

Allen, Jr, L.V., see Seth, S.C. (106) 7

Alonso, M.J., see Calvo, P. (103) 283

Alvarez, A.I., see Del Estal, J.L. (102) 257

Amdidouche, D., Montassier, P., Poelman, M.-C. and Duchêne, D.
Evaluation by laser Doppler velocimetry of the attenuation of tretinoin induced skin irritation by β-cyclodextrin complexation (111) 111

Ammar, H.O., El-Ridy, M.S., Ghorab, M. and Ghorab, M.M.
Evaluation of the antischistosomal effect of praziquantel in a liposomal delivery system in mice (103) 237

Amstrong, D.J., see Perez-Marcos, B. (111) 251

Andreux, J.-P., see Leroy-Lechat, F. (101) 97

Andry, M.-C., see Edwards-Lévy, F. (103) 253

Angberg, M., see Sebhatu, T. (104) 135

Anguiano-Igea, S., see Ganza-Gonzalez, A. (106) 179

Anguiano Igea, S., see García González, N. (104) 107

Antipas, A.S., Vander Velde, D. and Stella, V.J.
Factors affecting the deamidation of vancomycin in aqueous solutions (109) 261

Arakawa, T., see Niven, R.W. (109) 17

Armstrong, J.K., see Buckton, G. (110) 179

Artursson, P., see Toth, I. (102) 223

Artursson, P., see Toth, I. (105) 241
Asuero, A.G., see González, A.G. (108) 149
Atcheva, M., Simeonova, M., Boeva, M. and Konstantinov, C.
Effect of polybutylcyano acrylate nanoparticles on primary immune response of mice to sheep erythrocytes (103) 303
Attwood, D., see Burns, S.J. (110) 291
Attwood, D., see Burrows, R. (111) 283
Attwood, D., see Higginbottom, S. (109) 173
Audus, K.L., see Borchard, G. (110) 29
Audus, K.L., see Zheng, H. (101) 121
Augsburger, L.L., see Torrado, J.J. (106) 149
Aungst, B.J.
Site-dependence and structure-effect relationships for alkylglycosides as transmucosal absorption promoters for insulin (105) 219
Aungst, B.J., see Hussain, M.A. (105) 7
Ausborn, M., see Engel, A. (107) 99
Avramoff, A., see Hoffman, A. (111) 197
Azemar, N., see García-Celma, M.J. (105) 77

Babler, M., see Kararli, T.T. (102) 177
Bae, Y.H., see Cremers, H.F.M. (110) 117
Baert, L. and Down, G.R.B.
A comparison of two methods of instrumenting a small-scale basket extruder (107) 219
Baert, L., see Van der Meeren, P. (106) 89
Baert, L., see Vervaet, C. (107) 29
Baert, L., see Vervaet, C. (108) 207
Bai, J.P.F.
Effects of bile salts on brush-border and cytosolic proteolytic activities of intestinal enterocytes (111) 147
Bai, J.P.F.
Stability of neurotensin and acetylneurotensin 8–13 in brush-border membrane, cytosol, and homogenate of rat small intestine (112) 133
Bai, J.P.F.
The regional differences in the mucosal-cell lysosomal proteases within the rat small intestine (107) 133
Barker, S.A., Taylor, K.M.G. and Short, M.D.
The deposition and clearance of liposome entrapped ^{99m}Tc-DTPA in the human respiratory tract (102) 159
Barnes, D., see Kochhar, S.K. (112) 225
Barnwell, S.G., see Burns, S.J. (110) 291
Barnwell, S.G., see Higginbottom, S. (109) 173
Barthes, D., see Rochard, E. (101) 257
Barzegar-Jalali, M. and Hanaee, J.
Model for solubility estimation in mixed solvent systems (109) 291
Bashir, A.K., see Tanira, M.O.M. (102) 267
Bausch, A. and Leuenberger, H.
Wet spherical agglomeration of proteins as a new method to prepare parenteral fast soluble dosage forms (101) 63
Bayley, D.L., see Steward, A. (104) 145
Beall, H., Prankerd, R. and Sloan, K.
Transdermal delivery of 5-fluorouracil (5-FU) through hairless mouse skin by 1-alkyloxycarbonyl-5-FU prodrugs: Physicochemical characterization of prodrugs and correlations with transdermal delivery (111) 223
Bechgaard, E., Riis, K.J. and Jørgensen, L.
The development of an Usssing chamber technique for isolated human vaginal mucosa, and the viability of the in vitro system (106) 237
Bechgaard, E., see Jørgensen, L. (107) 231
Beezer, A.E., see Buckton, G. (110) 179
Begtrup, M., see Thomsen, K.F. (112) 143
Beijnen, J.H., see Van der Houwen, O.A.G.J. (105) 249
Beijnen, J.H., see Van der Houwen, O.A.G.J. (109) 191
Beijnen, J.H., see Van der Houwen, O.A.G.J. (112) 97
Bekers, O., see Van der Houwen, O.A.G.J. (105) 249
Bekers, O., see Van der Houwen, O.A.G.J. (112) 97
Benaji, B., Dine, T., Goudaliez, F., Luyckx, M., Brunet, C., Mallevais, M.L., Gressier, B., Cazin, M. and Cazin, J.C.
Compatibility study of methotrexate with PVC bags after repackaging into two types of infusion admixtures (105) 83
Bendas, G., see Engel, A. (107) 99
Benedetti, L., see Hume, L.R. (111) 295
Benedetti, L., see Sanzgiri, Y.D. (107) 91
Benghalem, A., see Sébert, P. (110) 285
Benita, S., see Zeevi, A. (108) 57
Benoît, J.P., see Le Ray, A.M. (106) 201
Bergren, M.S.
An automated controlled atmosphere microbalance for the measurement of moisture sorption (103) 103
Bergum, J.S., see Desai, D.S. (110) 249
Bergum, J.S., see Desai, D.S. (110) 257
Bergum, J.S., see Patel, N.K. (110) 203
Bermejo, M.V., see Garrigues, T.M. (101) 209
Bermejo, M.V., see Segura-Bono, M.J. (107) 159
Bernatchez, S.F., Tabatabay, C. and Gurny, R.
Sodium hyaluronate as a vehicle for an improved tolerance of 5-fluorouracil administered subconjunctivally to rabbits (106) 161
Bertelsen, P., Christensen, F.N., Holm, P. and Jørgensen, K.
Comparison of organic solvent-based ethylcellulose coatings on KCl crystals applied by top and bottom spraying in fluidized-bed equipment (111) 117
Bertoni, M., see Ferrari, F. (109) 115
Bertoni, M., see Ferrari, F. (112) 29
Bertoni, M., see Rizk, S. (112) 125
Beten, D.B. and Moës, A.J.
Controlled-release coevaporates of dipyridamole prepared with acrylic polymers (103) 243
Bettini, R., see Hariharan, D. (112) 47
Bevan, B., see Clemessy, M. (101) 219
Bittner, S., see Kararli, T.T. (102) 177
Blackhall, N.W., see Jenkins, P.G. (102) 261
Blanchard, J., see Ugwu, S.O. (102) 193
Blanco-Méndez, J., see Ganza-Gonzalez, A. (106) 179
Blanco Fuente, H., see García González, N. (104) 107
Blanco Méndez, J., see García González, N. (104) 107
Blanco Prieto, M.J., Delie, F., Fattal, E., Tartar, A., Puisieux, F., Gulik, A. and Couvreur, P.
Characterization of V3 BRU peptide-loaded small PLGA

microspheres prepared by a $(w_1/o)w_2$ emulsion solvent evaporation method (111) 137
Bleich, J., Kleinebudde, P. and Müller, B.W.
Influence of gas density and pressure on microparticles produced with the ASES process (106) 77
Bodmeier, R. and Paeratakul, O.
The distribution of plasticizers between aqueous and polymer phases in aqueous colloidal polymer dispersions (103) 47
Boeva, M., see Atcheva, M. (103) 303
Bolhuis, G.K., see Zuurman, K. (102) 1
Bolton, S., see Khan, M.A. (102) 185
Bonina, F.P. and Montenegro, L.
Effects of some non-toxic penetration enhancers on in vitro heparin skin permeation from gel vehicles (111) 191
Bonina, F.P. and Montenegro, L.
Vehicle effects on in vitro heparin release and skin penetration from different gels (102) 19
Bonina, F.P., Castelli, F., Montenegro, L. and Mazzone, G.
Partitioning and differential scanning calorimetry studies of *N*-alkyllactame ester dermal prodrugs of indomethacin (106) 115
Borchard, G., Audus, K.L., Shi, F. and Kreuter, J.
Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers (110) 29
Bourbouze, R., see Nimier, K. (105) 235
Bourny, E., see Sébert, P. (110) 285
Bourny, E., see Sébert, P. (106) 103
Bouzon, J., see Ouriemchi, E.M. (102) 47
Brain, J.D., see Niven, R.W. (104) 73
Bray, D., see Rowe, R.C. (101) 169
Briggner, L.-E., Buckton, G., Bystrom, K. and Darcy, P.
The use of isothermal microcalorimetry in the study of changes in crystallinity induced during the processing of powders (105) 125
Brittain, H.G., see Morris, K.R. (108) 195
Brossard, F., see Zeevi, A. (108) 57
Bruneaux, F., see Sautou, V. (107) 111
Brunet, C., see Benaji, B. (105) 83
Brunet, C., see Faouzi, M.A. (105) 89
Brunet, C., see Gressier, B. (104) 151
Buckton, G., Armstrong, J.K., Chowdhry, B.Z., Leharne, S. and Beezer, A.E.
The use of high sensitivity differential scanning calorimetry to characterise dilute aqueous dispersions of surfactants: 2. Further studies on polyoxyethylene alkyl ethers (110) 179
Buckton, G., see Briggner, L.-E. (105) 125
Buckton, G., see Mackellar, A.J. (112) 65
Buckton, G., see Mackellar, A.J. (112) 79
Buckton, G., see Sheridan, P.L. (109) 155
Bugay, D.E., see Morris, K.R. (108) 195
Bult, A., see Van der Houwen, O.A.G.J. (105) 249
Bult, A., see Van der Houwen, O.A.G.J. (109) 191
Bult, A., see Van der Houwen, O.A.G.J. (112) 97
Bundgaard, H., see Nielsen, L.S. (102) 231
Burns, S.J., Higginbottom, S., Corness, D., Hay, G., Whelan, I., Attwood, D. and Barnwell, S.G.
A study of enteric-coated liquid-filled hard gelatin capsules with biphasic release characteristics (110) 291
Burns, S.J., see Higginbottom, S. (109) 173
Burrows, R., Collett, J.H. and Attwood, D.
The release of drugs from monoglyceride-water liquid crystalline phases (111) 283
Byron, P.R., see Phillips, E.M. (110) 9
Bystrom, K., see Briggner, L.-E. (105) 125

Calpena, A.C., Lauroba, J., Suriol, M., Obach, R. and Domenech, J.
Effect of d-limonene on the transdermal permeation of nifedipine and domperidone (103) 179
Calvo, P., Thomas, C., Alonso, M.J., Vila-Jato, J.L. and Robinson, J.R.
Study of the mechanism of interaction of poly(ε-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy (103) 283
Cannon, J.B., see Lovell, M.W. (109) 45
Caraballo, I., Fernandez-Arevalo, M., Holgado, M.A., Rabasco, A.M. and Leuenberger, H.
Study of the release mechanism of carteolol inert matrix tablets on the basis of percolation theory (109) 229
Caramella, C., see Ferrari, F. (109) 115
Caramella, C., see Ferrari, F. (112) 29
Caramella, C., see Rizk, S. (112) 125
Carlucci, G., Mazzeo, P., Vetuschi, C. and Di Giuseppe, E.
Reversed-phase high-performance liquid chromatographic and derivative UV spectrophotometric determination of famotidine in pharmaceutical preparations (102) 271
Carson, J.H., see Lamson, M.J. (105) 259
Carstensen, J.T., see Franchini, M.K. (111) 153
Carvajal, M.T., see Shah, N.H. (106) 15
Casalderrey, M., see Landín, M. (107) 247
Castelli, F., Conti, B., Puglisi, G., Conte, U. and Mazzone, G.
Calorimetric studies on tolmetin release from poly-DL-lactide microspheres to lipid model membrane (103) 217
Castelli, F., see Bonina, F.P. (106) 115
Casu, B., see Ahmed, S.M. (109) 99
Catz, P., see Nolen III, H.W. (107) 169
Cavallaro, G., Fresta, M., Giammona, G., Puglisi, G. and Villari, A.
Entrapment of β-lactams antibiotics in polyethylcyanoacrylate nanoparticles: Studies on the possible in vivo application of this colloidal delivery system (111) 31
Cavallaro, G., see Giammona, G. (105) 57
Cavalli, R., see Morel, S. (105) R1
Cazin, J.C., see Benaji, B. (105) 83
Cazin, J.C., see Faouzi, M.A. (105) 89
Cazin, J.C., see Gressier, B. (104) 151
Cazin, M., see Benaji, B. (105) 83
Cazin, M., see Faouzi, M.A. (105) 89
Cazin, M., see Gressier, B. (104) 151
Cedro, A., see Ahmed, S.M. (109) 99
Çelebi, N., see Şener, E. (110) 109

Çelik, M., see Maganti, L. (103) 55
Cerezo, A., see Margarit, M.V. (108) 101
Chafetz, L., see Neau, S.H. (108) 95
Chafetz, L., see Shah, K.P. (109) 271
Challacombe, S.J., see O'Hagan, D.T. (108) 133
Chan, L.W., see Wan, L.S.C. (103) 267
Chang, L.-C., see Kitamura, S. (101) 127
Chang, P., see Law, S.L. (103) 81
Chapman, Jr, J.M., see Michniak, B.B. (110) 231
Charman, W.N., see Doherty, M.M. (111) 205
Charman, W.N., see Pochopin, N.L. (105) 169
Chauvet, A., see El Moussaoui, A. (106) 109
Chawla, A., Taylor, K.M.G., Newton, J.M. and Johnson, M.C.R.
Production of spray dried salbutamol sulphate for use in dry powder aerosol formulation (108) 233
Chen, D., Ohta, N., Yotsuyanagi, T. and Ikeda, K.
Polymerized precipitation of human γ-globulin induced by *cis*-diamminedichloroplatinum(II) (106) 249
Chess, E.K., see Jenke, D.R. (108) 1
Chester, D.C., see Lamson, M.J. (105) 259
Chetoni, P., Crotti, P. and Saettone, M.F.
Albuterol prodrugs for ocular administration: synthesis and evaluation of the physico-chemical and IOP-depressant properties of three albuterol triesters (105) 147
Chevanne, F., see Le Corre, P. (107) 41
Chevrier, R., see Sautou, V. (107) 111
Chiang, C.-C., see Pavliv, L. (105) 227
Chiossone, D.C., see Smith, P.L. (106) 95
Choi, H.-G., see Kim, C.-K. (106) 25
Choi, J.-Y., see Kim, C.-K. (106) 25
Choi, K.E., see Yoon, W.H. (102) 249
Chopineau, J., see Sautou, V. (107) 111
Chow, D., see Shah, J.C. (109) 283
Chow, D.D., see Touitou, E. (104) 19
Chow, M.Y., see Neau, S.H. (108) 95
Chowdhry, B.Z., see Buckton, G. (110) 179
Chowdhry, B.Z., see Mackellar, A.J. (112) 65
Christensen, C.A., see Michniak, B.B. (110) 231
Christensen, F.N., see Bertelsen, P. (111) 117
Clancy, M.J., Corish, J. and Corrigan, O.I.
A comparison of the effects of electrical current and penetration enhancers on the properties of human skin using spectroscopic (FTIR) and calorimetric (DSC) methods (105) 47
Clark, A.R., see Newman, S.P. (102) 127
Clarson, S., see Hutchings, D. (104) 203
Clements, R., see Jones, H.P. (104) 253
Clemessy, M., Couarraze, G., Bevan, B. and Puisieux, F.
Preservation of skin permeability during in vitro iontophoretic experiments (101) 219
Climent, E., see Fabra-Campos, S. (109) 197
Coderch, L., Oliva, M., Pons, L. and Parra, J.L.
Percutaneous penetration in vivo of amino acids (111) 7
Colarte, A.I., see Heinämäki, J.T. (109) 9
Cole, E.T., see Kenyon, C.J. (112) 207
Collett, J.H., see Burrows, R. (111) 283
Colombo, P., see Hariharan, D. (112) 47
Concheiro, A., see Landín, M. (103) 9
Concheiro, A., see Landín, M. (107) 247
Concheiro, A., see Landín, M. (109) 1
Conte, U., see Castelli, F. (103) 217
Conti, B., see Castelli, F. (103) 217
Corbini, G., see Corti, P. (111) 83
Corish, J., see Clancy, M.J. (105) 47
Corness, D., see Burns, S.J. (110) 291
Corrigan, O.I., see Clancy, M.J. (105) 47
Corrigan, O.I., see O'Reilly, J.R. (105) 137
Corrigan, O.I., see O'Reilly, J.R. (109) 147
Cortesi, R., Esposito, E., Menegatti, E., Gambari, R. and Nastruzzi, C.
Gelatin microspheres as a new approach for the controlled delivery of synthetic oligonucleotides and PCR-generated DNA fragments (105) 181
Corti, P., Corbini, G., Gratteri, P., Furlanetto, S. and Pinzauti, S.
Determination of some quinolones in tablets, human plasma and urine by differential-pulse polarography (111) 83
Cotton, M.L., Lamarche, P., Motola, S. and Vadas, E.B.
L-649,923 – The selection of an appropriate salt form and preparation of a stable oral formulation (109) 237
Cotton, M.L., see Kwong, E.C. (103) 259
Couarraze, G., see Clemessy, M. (101) 219
Courtois, P., see Rochard, E. (101) 257
Couvreur, P., see Blanco Prieto, M.J. (111) 137
Couvreur, P., see Némati, F. (102) 55
Craig, D.Q.M., see Ah-Fat, N.M.W. (107) 239
Craig, D.Q.M., see Sutananta, W. (110) 75
Craig, D.Q.M., see Sutananta, W. (111) 51
Cremers, H.F.M., Seymour, L.W., Lam, K., Los, G., Van Vugt, M., Kwon, G., Bae, Y.H., Kim, S.W. and Feijen, J.
Adriamycin-loaded albumin-heparin conjugate microspheres for intraperitoneal chemotherapy (110) 117
Crotti, P., see Chetoni, P. (105) 147
Cserháti, T. and Holló, J.
Interaction of taxol and other anticancer drugs with hydroxypropyl-β-cyclodextrin (108) 69
Cumming, K.I. and Winfield, A.J.
In vitro evaluation of a series of sodium carboxylates as dermal penetration enhancers (108) 141

Danckwerts, M.P.
Development of a zero-order release oral compressed tablet with potential for commercial tabletting production (112) 37
Darcy, P., see Briggner, L.-E. (105) 125
Da Silva, C.P., De Oliveira, C.R. and De Lima, M.C.P.
In vitro assay of the effects of anticancer drugs on leukemic T-cells by flow microcalorimetry (111) 25
Davidson, R., Ek, R. and Ragnarsson, G.
Determination of the expansion characteristics of porous cellulose matrices by image analysis (112) 153
Davies, M.C., see Watts, P.J. (102) 101

Davies, N.M., Farr, S.J., Kellaway, I.W., Taylor, G. and Thomas, M.
A comparison of the gastric retention of alginate containing tablet formulations with and without the inclusion of excipient calcium ions (105) 97
Davis, A.F., see Pellett, M.A. (111) 1
Davis, S.S., see Jenkins, P.G. (102) 261
Davis, S.S., see Nankervis, R. (101) 249
Davis, S.S., see O'Hagan, D.T. (103) 37
Davis, S.S., see Wilding, I.R. (101) 263
Davis, S.S., see Wilding, I.R. (111) 99
Day, N.H., see Nankervis, R. (101) 249
Dayan, N., see Touitou, E. (103) 131
De Eulate, J.A., see Veiga, M.D. (110) 223
De Greef, H., see Kinget, R. (110) 65
De Groot, J.S., see Roy, S.D. (110) 137
Deharo, E., see Mbela, T.K.M.N. (110) 189
Del Estal, J.L., Alvarez, A.I., Villaverde, C., Justel, A. and Prieto, J.G.
Increased systemic bioavailability of albendazol when administered with surfactants in rats (102) 257
Delgado Charro, B., see García González, N. (104) 107
Delie, F., see Blanco Prieto, M.J. (111) 137
De Lima, M.C.P., see Da Silva, C.P. (111) 25
DeLuca, P.P., see Lee, K.C. (106) 167
De Muynck, C., Lefebvre, R.A. and Remon, J.P.
Study of the bioavailability of four indomethacin suppository formulations in healthy volunteers (104) 87
De Muynck, C., Lefebvre, R.A. and Remon, J.P.
The influence of formulation on the relative bioavailability of indomethacin suppositories in dogs and rabbits (104) 1
DeNoto, A.R., see Thombre, A.G. (111) 181
De Oliveira, C.R., see Da Silva, C.P. (111) 25
Desai, D.S., Abdelnasser, M.A., Rubitski, B.A. and Varia, S.A.
Photostabilization of uncoated tablets of sorivudine and nifedipine by incorporation of synthetic iron oxides (103) 69
Desai, D.S., Rubitski, B.A., Bergum, J.S. and Varia, S.A.
Effects of different types of lactose and disintegrant on dissolution stability of hydrochlorothiazide capsule formulations (110) 257
Desai, D.S., Rubitski, B.A., Bergum, J.S. and Varia, S.A.
Effects of various formulation factors on dissolution stability of aztreonam, hydrochlorothiazide, and sorivudine capsules (110) 249
Desai, D.S., Rubitski, B.A., Varia, S.A. and Huang, M.H.
Effect of formaldehyde formation on dissolution stability of hydrochlorothiazide bead formulations (107) 141
Deutsch, J., see Touitou, E. (103) 199
De Verdière, A.C., see Némati, F. (102) 55
Di Giuseppe, E., see Carlucci, G. (102) 271
Dine, T., see Benaji, B. (105) 83
Dine, T., see Faouzi, M.A. (105) 89
Dine, T., see Gressier, B. (104) 151
Dirix, C.A.M.C., see IJntema, K. (112) 215
Doherty, M.M., Hughes, P.J., Kim, S.R., Mainwaring, D.E. and Charman, W.N.
Effect of lyophilization on the physical characteristics of medium molecular mass hyaluronates (111) 205
Domenech, J., see Calpena, A.C. (103) 179
Dominguez-Gil Hurlé, A., see Macías Sánchez, B. (106) 229
Down, G.R.B., see Baert, L. (107) 219
Down, G.R.B., see Kwong, E.C. (103) 259
Dubernet, C., see Némati, F. (102) 55
Duchêne, D., see Amdidouche, D. (111) 111
Duchêne, D., see Leroy-Lechat, F. (101) 97
Duchêne, D., see Lin, S.-Z. (106) 63
Duncan-Hewitt, W.C., see Lin, M.-C. (106) 187
Duncan, R., see Pató, J. (104) 227
Du Plessis, J., Ramachandran, C., Weiner, N. and Müller, D.G.
The influence of particle size of liposomes on the deposition of drug into skin (103) 277
Du Plessis, J., Weiner, N. and Müller, D.G.
The influence of in vivo treatment of skin with liposomes on the topical absorption of a hydrophilic and a hydrophobic drug in vitro (103) R1
Durmaz, G., see Akbuğa, J. (111) 217
Duru, C., see Rizk, S. (112) 125

Ebert, C., see Zhang, J. (101) 15
Edwards-Lévy, F., Andry, M.-C. and Lévy, M.-C.
Determination of free amino group content of serum albumin microcapsules: II. Effect of variations in reaction time and in terephthaloyl chloride concentration (103) 253
Eissens, A.C., see Te Wierik, G.H.P. (102) 81
Ek, R., Alderborn, G. and Nyström, C.
Particle analysis of microcrystalline cellulose: Differentiation between individual particles and their agglomerates (111) 43
Ek, R., see Davidson, R. (112) 153
El-Bagory, I., Reid, B.D. and Mitchell, A.G.
The effect of gamma radiation on the tableting properties of some pharmaceutical excipients (105) 255
El-Ridy, M.S., see Ammar, H.O. (103) 237
El-Sayed, Y.M., Al-Meshal, M.A., Al-Angary, A.A., Al-Balla, S.R. and Gouda, M.W.
Effects of oral administration of colestipol and cholestyramine on the pharmacokinetics of ketoprofen administered intramuscularly in man (109) 107
El-Sayed, Y.M., see Hosny, E.A. (112) 87
Elamin, A.A., Ahlneck, C., Alderborn, G. and Nyström, C.
Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure (111) 159
Elamin, A.A., Alderborn, G. and Ahlneck, C.
The effect of pre-compaction processing and storage conditions on powder and compaction properties of some crystalline materials (108) 213
Elliott, P.N.C., see Perez-Marcos, B. (111) 251
El Moussaoui, A., Chauvet, A., Masse, J., Gaudy, D. and Puech, A.
Lyoavailability of nordazepam solid dispersions in relation with phase diagrams (106) 109
Emori, H., see Yamamoto, K. (102) 133

Engel, A., Bendas, G., Wilhelm, F., Mannova, M., Ausborn, M. and Nuhn, P.
Freeze drying of liposomes with free and membrane-bound cryoprotectants – the background of protection and damaging processes (107) 99
Eriksson, M. and Alderborn, G.
Mechanisms for post-compaction changes in tensile strength of sodium chloride compacts prepared from particles of different dimensions (109) 59
Esposito, E., see Cortesi, R. (105) 181
Eyer, P., see Thiermann, H. (109) 35

Fabra-Campos, S., Climent, E., Sanchis-Cortés, A. and Plá-Delfina, J.M.
Compared effects of synthetic and natural bile acid surfactants on xenobiotic absorption: IV. Studies with taurocholate in the rat small intestine (109) 197
Fakes, M.G., see Morris, K.R. (105) 209
Falkner, F.C., see Thombre, A.G. (111) 181
Faouzi, M.A., Dine, T., Luyckx, M., Gressier, B., Goudaliez, F., Mallevais, M.L., Brunet, C., Cazin, M. and Cazin, J.C.
Leaching of diethylhexyl phthalate from PVC bags into intravenous teniposide solution (105) 89
Farhadieh, B., see Kararli, T.T. (102) 177
Farr, S.J., see Davies, N.M. (105) 97
Farrar, C., see Niven, R.W. (109) 17
Fattal, E., see Blanco Prieto, M.J. (111) 137
Feijen, J., see Cremers, H.F.M. (110) 117
Femi-Oyewo, M.N. and Spring, M.S.
Studies on paracetamol crystals produced by growth in aqueous solutions (112) 17
Fernandez-Arevalo, M., see Caraballo, I. (109) 229
Fernández-Hervás, M.-J., Holgado, M.-A., Rabasco, A.-M. and Fini, A.
Use of fractal geometry on the characterization of particles morphology: Application to the diclofenac hydroxyethylpirrolidine salt (108) 187
Ferrari, F., Bertoni, M., Caramella, C. and La Manna, A.
Description and validation of an apparatus for gel strength measurements (109) 115
Ferrari, F., Bertoni, M., Caramella, C. and Waring, M.J.
Comparative evaluation of hydrocolloid dressings by means of water uptake and swelling force measurements: I (112) 29
Ferrari, F., see Rizk, S. (112) 125
Ferreira, L.A.M., Seiller, M., Grossiord, J.L., Marty, J.P. and Wepierre, J.
Vehicle influence on in vitro release of metronidazole: role of w/o/w multiple emulsion (109) 251
Fini, A., see Fernández-Hervás, M.-J. (108) 187
Finley, R., see Adjei, A. (107) 57
Flinn, N., see Toth, I. (105) 241
Florence, A.T., see Jani, P.U. (105) 157
Florence, A.T., see Yoshioka, T. (105) 1
Florence, A.T., see Yoshioka, T. (108) 117
Ford, J.L., see Francomb, M.M. (103) 87
Ford, J.L., see Perez-Marcos, B. (111) 251
Fort, F., see Adjei, A. (107) 57
Fort, J.J. and Mitra, A.K.
Development of a physical model for simultaneous diffusion/bioconversion of methotrexate dialkyl esters: A potential parallel/sequential metabolic scheme (107) 9
Fort, J.J. and Mitra, A.K.
Effects of epidermal/dermal separation methods and ester chain configuration on the bioconversion of a homologous series of methotrexate dialkyl esters in dermal and epidermal homogenates of hairless mouse skin (102) 241
Fournier, C., Hamon, M., Hamon, M., Wannebroucq, J., Petiprez, S., Pruvo, J.-P. and Hecquet, B.
Preparation and preclinical evaluation of bioresorbable hydroxyethylstarch microspheres for transient arterial embolization (106) 41
Fowler, S., see Jones, D.S. (105) 71
Fox, R., see Hastewell, J. (101) 115
Franchini, M.K. and Carstensen, J.T.
Failure of high temperature extrapolation of oxidative reactions in solution (111) 153
Francomb, M.M., Ford, J.L. and Lee, M.G.
Adsorption of vincristine, vinblastine, doxorubicin and mitozantrone to in-line intravenous filters (103) 87
Freebern, K., see Pavliv, L. (105) 227
Freeman, S., see Walker, I. (104) 157
Freeman, S., see Walker, I. (108) 225
Fresta, M., see Cavallaro, G. (111) 31
Friend, D.R., see Nolen III, H.W. (107) 169
Friðriksdóttir, H., see Loftsson, T. (104) 181
Friðriksdóttir, H., see Loftsson, T. (110) 169
Fuhrman, L.C., see Michniak, B.B. (110) 231
Fujioka, Y., see Motozono, H. (108) 39
Fujita, T., see Takakura, Y. (105) 19
Furitsu, H., see Takakura, Y. (105) 19
Furlanetto, S., see Corti, P. (111) 83
Furlani, P., see Wilding, I.R. (111) 99

Gabriel, D.L., see Kearney, A.S. (104) 169
Gabrijelčič, V., Šentjurc, M. and Schara, M.
The measurement of liposome entrapped molecules' penetration into the skin: A 1D-EPR and EPR kinetic imaging study (102) 151
Gajan, V., see Le Corre, P. (107) 41
Gambari, R., see Cortesi, R. (105) 181
Gamlen, M.J., see Jones, H.P. (104) 253
Ganderton, D., see Timsina, M.P. (101) 1
Ganza-Gonzalez, A., Vila-Jato, J.L., Anguiano-Igea, S., Otero-Espinar, F.J. and Blanco-Méndez, J.
A proton nuclear magnetic resonance study of the inclusion complex of naproxen with β-cyclodextrin (106) 179
García-Celma, M.J., Azemar, N., Pes, M.A. and Solans, C.
Solubilization of antifungal drugs in water/POE(20) sorbitan monooleate/oil systems (105) 77
García González, N., Kellaway, I.W., Blanco Fuente, H., Anguiano Igea, S., Delgado Charro, B., Otero Espinar, F.J. and Blanco Méndez, J.
Influence of glycerol concentration and carbopol molecu-

lar weight on swelling and drug release characteristics of metoclopramide hydrogels (104) 107
Garrigues, T.M., Segura-Bono, M.J., Bermejo, M.V., Merino, V. and Plá-Delfina, J.M.
Compared effects of synthetic and natural bile acid surfactant on xenobiotic absorption. II. Studies with sodium glycocholate to confirm a hypothesis (101) 209
Garrigues, T.M., see Segura-Bono, M.J. (107) 159
Gasco, M.R., see Morel, S. (105) R1
Gašperlin, M., Kristl, J., Šmid-Korbar, J. and Kerč, J.
The structure elucidation of semisolid w/o emulsion systems containing silicone surfactant (107) 51
Gaudy, D., see El Moussaoui, A. (106) 109
Gaudy, D., see Rizk, S. (112) 125
Gautier, J.C., see Le Ray, A.M. (106) 201
Gazzaniga, A., Iamartino, P., Maffione, G. and Sangalli, M.E.
Oral delayed-release system for colonic specific delivery (108) 77
Gazzaniga, A., see Wilding, I.R. (111) 99
Ghanem, A.-H., see Inamori, T. (105) 113
Ghodbane, S., see Rivera, S.L. (108) 31
Ghorab, M., see Ammar, H.O. (103) 237
Ghorab, M.M., see Ammar, H.O. (103) 237
Giammona, G., Cavallaro, G., Pitarresi, G., Ventura, C. and Palazzo, S.
Synthesis and therapeutic potential of a macromolecular prodrug of diflunisal (105) 57
Giammona, G., see Cavallaro, G. (111) 31
Gibbons, W.A., see Toth, I. (105) 241
Gjellan, K. and Graffner, C.
Comparative dissolution studies of rectal formulations using the basket, the paddle and the flow-through methods: II. Ibuprofen in suppositories of both hydrophilic and lipophilic types (112) 233
Gjellan, K. and Graffner, C.
Influence of amount of hard fat in suppositories on the in vitro release rate and bioavailability of paracetamol. II. A comparison between three compositions and a rectal solution (104) 215
Gjellan, K., Graffner, C. and Quiding, H.
Influence of amount of hard fat in suppositories on the in vitro release rate and bioavailability of paracetamol and codeine. I. A comparison of three suppository compositions in vivo (102) 71
Gjellan, K., Graffner, C. and Strid, S.
Exploratory studies on the in vitro release and bioavailability of dextropropoxyphene from lipophilic and hydrophilic suppositories (102) 213
Go, L.T., see Zanen, P. (107) 211
Gochoco, C.H., Ryan, F.M., Miller, J., Smith, P.L. and Hidalgo, I.J.
Uptake and transepithelial transport of the orally absorbed cephalosporin cephalexin, in the human intestinal cell line, Caco-2 (104) 187
Goidas, P., see Malamataris, S. (103) 205
Goldberg, E.P., see Jayakrishnan, A. (106) 221
Golomb, G., see Hoffman, A. (111) 197
Gómez-Amoza, J.L., see Landín, M. (103) 9
Gómez-Amoza, J.L., see Landín, M. (107) 247
Gómez-Amoza, J.L., see Landín, M. (109) 1
Gong, J.-P., see Kim, C.-K. (106) 25
González, A.G., Herrador, M.A. and Asuero, A.G.
Solubility of theophylline in aqueous *N,N*-dimethylformamide mixtures (108) 149
Goskonda, S.R., Hileman, G.A. and Upadrashta, S.M.
Controlled release pellets by extrusion-spheronization (111) 89
Gottfries, J., Ahlbom, J., Harang, V., Johansson, E., Josefson, M., Morsing, T., Pettersson, A. and Torstensson, A.
Validation of an extended release tablet dissolution testing system using design and multivariate analysis (106) 141
Gouda, M.W., see El-Sayed, Y.M. (109) 107
Goudaliez, F., see Benaji, B. (105) 83
Goudaliez, F., see Faouzi, M.A. (105) 89
Graffner, C., see Østberg, T. (111) 271
Graffner, C., see Østberg, T. (112) 241
Graffner, C., see Gjellan, K. (102) 213
Graffner, C., see Gjellan, K. (102) 71
Graffner, C., see Gjellan, K. (104) 215
Graffner, C., see Gjellan, K. (112) 233
Gratteri, P., see Corti, P. (111) 83
Gregoriadis, G., see McCormack, B. (112) 249
Gremeau, I., see Sautou, V. (107) 111
Gressier, B., Lebegue, S., Brunet, C., Dine, T., Luyckx, M., Cazin, M. and Cazin, J.C.
The effect of mesna in reversing, in vitro, the protease-antiprotease imbalance: Its reaction on the MPO-H_2O_2 system and on human leukocyte elastase (104) 151
Gressier, B., see Benaji, B. (105) 83
Gressier, B., see Faouzi, M.A. (105) 89
Grinberg, L.N., see Tønnesen, H.H. (110) 161
Grossiord, J.L., see Ferreira, L.A.M. (109) 251
Guerrini, M., see Ahmed, S.M. (109) 99
Guillory, J.K., see Kitamura, S. (101) 127
Gulik, A., see Blanco Prieto, M.J. (111) 137
Gupta, P.K. and Robinson, J.R.
Effect of meal viscosity on gastric pH and residual volume in the fasted dog (109) 91
Gupta, P.K., see Lovell, M.W. (109) 45
Gurny, R., see Bernatchez, S.F. (106) 161
Gutiérrez-Rocca, J.C. and McGinity, J.W.
Influence of water soluble and insoluble plasticizers on the physical and mechanical properties of acrylic resin copolymers (103) 293
Guy, R.H., see Singh, P. (101) R1

Hadgraft, J., see Pellett, M.A. (111) 1
Hadgraft, J., see Pugh, W.J. (103) 163
Haemers, A., see Mbela, T.K.M.N. (110) 189
Hakasalo, M., see Mönkkönen, J. (107) 189
Hamon, M., see Fournier, C. (106) 41
Hamon, M., see Fournier, C. (106) 41
Han, J.-H., see Kim, C.-K. (108) 21
Han, S.-K., see Kim, C.-K. (101) 191

Hanaee, J., see Barzegar-Jalali, M. (109) 291
Hancock, B.C., York, P. and Rowe, R.C.
An assessment of substrate-binder interactions in model wet masses. 1: Mixer torque rheometry (102) 167
Handa, T., see Kakee, A. (111) 15
Harang, V., see Gottfries, J. (106) 141
Hardie, L., see Taylor, R.B. (102) 201
Hariharan, D., Peppas, N.A., Bettini, R. and Colombo, P.
Mathematical analysis of drug delivery from swellable systems with partial physical restrictions or impermeable coatings (112) 47
Harron, D.W.G., see Tanira, M.O.M. (102) 267
Hashida, M., see Takakura, Y. (105) 19
Hasinoff, B.B.
An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its one-ring opened intermediates (107) 67
Hassan, H., see Sakellariou, P. (102) 207
Hastewell, J., Lynch, S., Fox, R., Williamson, I., Skelton-Stroud, P. and Mackay, M.
Enhancement of human calcitonin absorption across the rat colon in vivo (101) 115
Hata, T., Shimazaki, Y., Kagayama, A., Tamura, S. and Ueda, S.
Development of a novel drug delivery system, time-controlled explosion system (TES): V. Animal pharmacodynamic study and human bioavailability study (110) 1
Hauss, D.J., Mehta, S.C. and Radebaugh, G.W.
Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via a formulation approach (108) 85
Hay, G., see Burns, S.J. (110) 291
Hearn, D.J., see Jones, H.P. (104) 253
Hecquet, B., see Fournier, C. (106) 41
Heinämäki, J.T., Colarte, A.I., Nordström, A.J. and Yliruusi, J.K.
Comparative evaluation of ammoniated aqueous and organic-solvent-based cellulose ester enteric coating systems: a study on free films (109) 9
Heinämäki, J.T., Lehtola, V.-M., Nikupaavo, P. and Yliruusi, J.K.
The mechanical and moisture permeability properties of aqueous-based hydroxypropyl methylcellulose coating systems plasticized with polyethylene glycol (112) 191
Heinemann, S., see Müller, R.H. (107) 121
Heinemann, S., see Müller, R.H. (101) 175
Heinonen, R.M., see Salomies, H.E.M. (110) 197
Heiskanen, I., see Veski, P. (111) 171
Hempenstall, J.M., see Wilding, I.R. (101) 263
Heng, P.W.S., see Wan, L.S.C. (103) 267
Henriksen, I., Smistad, G. and Karlsen, J.
Interactions between liposomes and chitosan (101) 227
Herbette, L.G., see Lamson, M.J. (105) 259
Herrador, M.A., see González, A.G. (108) 149
Heuvelsland, W.J.M., see IJntema, K. (112) 215
Hibi, T., see Kakee, A. (111) 15
Hidalgo, I.J., see Gochoco, C.H. (104) 187
Hidalgo, I.J., see Smith, P.L. (106) 95
Higginbottom, S., Mallinson, C.B., Burns, S.J., Attwood, D. and Barnwell, S.G.
Ursodeoxycholic acid: Effects of formulation on in vitro dissolution (109) 173
Higginbottom, S., see Burns, S.J. (110) 291
Higuchi, W.I., see Inamori, T. (105) 113
Hileman, G.A., see Goskonda, S.R. (111) 89
Hileman, G.A., see Upadrashta, S.M. (112) 173
Hillery, A., see Toth, I. (105) 241
Hillery, A.M., see Toth, I. (102) 223
Hino, T., see Morishima, K. (105) 11
Hirakawa, Y., see Narisawa, S. (104) 95
Ho, A.H.L., Popat, S.C. and Sugden, J.K.
Some effects of metal ions on the photogeneration of hydroxyl radicals (104) 247
Ho, A.H.L., Puri, A. and Sugden, J.K.
Effect of sweetening agents on the light stability of aqueous solutions of L-ascorbic acid (107) 199
Hoffman, A., Nyska, A., Avramoff, A. and Golomb, G.
Continuous versus pulsatile administration of erythropoietin (EPO) via the uterus in anemic rats (111) 197
Hoffman, A.J., see Shao, Z. (112) 181
Hogan, J.E., see Perez-Marcos, B. (111) 251
Holgado, M.-A., see Fernández-Hervás, M.-J. (108) 187
Holgado, M.A., see Caraballo, I. (109) 229
Hollingworth, A., see Newman, S.P. (102) 127
Holló, J., see Cserháti, T. (108) 69
Holm, P., see Bertelsen, P. (111) 117
Holzner, P.M. and Müller, B.W.
An in vitro evaluation of various spacer devices for metered-dose inhalers using the Twin Impinger (106) 69
Hooper, G., see Steed, K.P. (112) 199
Hosny, E.A., El-Sayed, Y.M., Al-Meshal, M.A. and Al-Angary, A.A.
Effect of food on bioavailability of bioadhesive-containing indomethacin tablets in dogs (112) 87
Hosoya, K.-i., see Kubo, H. (103) 27
Houjou, T., see Katayama, N. (110) 155
Howard, K.A., see Jenkins, P.G. (102) 261
Howes, C., see Steward, A. (104) 145
Hruby, V., see Ugwu, S.O. (102) 193
Hsu, C.C., see Lovell, M.W. (109) 45
Hsu, L.-R., Huang, Y.-B., Wu, P.-C. and Tsai, Y.-H.
Percutaneous absorption of piroxicam from FAPG base through rat skin: effects of fatty acid added to FAPG base (106) 1
Hsu, L.-R., see Lin, H.-H. (112) 165
Hu, P., see Sinko, P.J. (109) 125
Huang, M.H., see Desai, D.S. (107) 141
Huang, Y.-B., see Hsu, L.-R. (106) 1
Huang, Y.-B., see Lin, H.-H. (112) 165
Hughes, P.J., see Doherty, M.M. (111) 205
Hui, H.-W., see Lovell, M.W. (109) 45

Hui, J., see Adjei, A. (107) 57
Hume, L.R., Lee, H.K., Benedetti, L., Sanzgiri, Y.D., Topp, E.M. and Stella, V.J.
Ocular sustained delivery of prednisolone using hyaluronic acid benzyl ester films (111) 295
Hussain, M.A. and Aungst, B.J.
Nasal mucosal metabolism of an LH-RH fragment and inhibition with boroleucine (105) 7
Hutchings, D., Clarson, S. and Sakr, A.
Studies of the mechanical properties of free films prepared using an ethylcellulose pseudolatex coating system (104) 203
Hwang, S.J., see Jeong, Y.N. (102) 35
Hyvönen-Dabek, M., see Mannermaa, J.P. (103) 125

Iamartino, P., see Gazzaniga, A. (108) 77
IJntema, K., Heuvelsland, W.J.M., Dirix, C.A.M.C. and Sam, A.P.
Hydroxyapatite microcarriers for biocontrolled release of protein drugs (112) 215
Ikeda, K., see Chen, D. (106) 249
Ikeda, T., see Tokui, T. (110) 277
Im, E.-B., see Kim, C.-K. (101) 191
Inada, Y., see Yoshimura, Y. (103) 1
Inamori, T., Ghanem, A.-H., Higuchi, W.I. and Srinivasan, V.
Macromolecule transport in and effective pore size of ethanol pretreated human epidermal membrane (105) 113
Infeld, M.H., see Shah, N.H. (106) 15
Ip, A.Y., see Niven, R.W. (101) 81
Ip, A.Y., see Niven, R.W. (109) 17
Irwin, W.J., see Walker, I. (104) 157
Irwin, W.J., see Walker, I. (108) 225
Ishida, O., see Maruyama, K. (111) 103
Ishigami, M., see Tokui, T. (110) 277
Ito, R., see Watanabe, Y. (110) 93
Iwaki, M., see Ogiso, T. (102) 141
Iwatsuru, M., see Maruyama, K. (111) 103

Jacob, M., see Rizk, S. (112) 125
Jakubowski, G., see Jenke, D.R. (108) 1
Jang, S.H., see Yoon, W.H. (102) 249
Jang, T.F., see Law, S.L. (103) 81
Jani, P.U., McCarthy, D.E. and Florence, A.T.
Titanium dioxide (rutile) particle uptake from the rat GI tract and translocation to systemic organs after oral administration (105) 157
Jansen, J., Treiner, C., Vaution, C. and Puisieux, F.
Surface modification of alumina particles by nonionic surfactants: Adsorption of steroids, barbiturates and pilocarpine (103) 19
Jayakrishnan, A., Knepp, W.A. and Goldberg, E.P.
Casein microspheres: preparation and evaluation as a carrier for controlled drug delivery (106) 221
Jeffery, H., see O'Hagan, D.T. (103) 37
Jeffery, H., see O'Hagan, D.T. (108) 133
Jenke, D.R., Chess, E.K. and Jakubowski, G.
Modeling of the leachables impact on the engineering of parenteral product container systems (108) 1
Jenkins, P.G., Howard, K.A., Blackhall, N.W., Thomas, N.W., Davis, S.S. and O'Hagan, D.T.
The quantitation of the absorption of microparticles into the intestinal lymph of Wistar rats (102) 261
Jenquin, M.R. and McGinity, J.W.
Characterization of acrylic resin matrix films and mechanisms of drug-polymer interactions (101) 23
Jeong, Y.N., Lee, S.H., Lee, M.G., Hwang, S.J. and Kim, C.-K.
Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing negatively charged liposomes to rats (102) 35
Jerzewski, R.L. and Lordi, N.G.
Water vapor diffusion in model tablet systems: I. Design of a diffusion apparatus (101) 35
Jerzewski, R.L. and Lordi, N.G.
Water vapor diffusion in model tablet systems: II. Experiments with lactose anhydrous based tablets (101) 45
Jian, L. and Li Wan Po, A.
Effect of angiotensin-converting enzyme (ACE) inhibitors on ciliary activity (107) 77
Jiménez-Castellanos, M.R., Zia, H. and Rhodes, C.T.
Design and testing in vitro of a bioadhesive and floating drug delivery system for oral application (105) 65
Jiménez-Castellanos, M.R., see Muñoz-Ruiz, A. (110) 37
Jiménez-Castellanos Ballesteros, M.R., see Velasco Antequera, M.V. (103) 155
Jing-ping, Z., see Ogiso, T. (102) 141
Johansson, E., see Gottfries, J. (106) 141
Johnson, H.W., see Lovell, M.W. (109) 45
Johnson, M.C.R., see Chawla, A. (108) 233
Jones, D.S. and Fowler, S.
A preliminary report concerning the effects of Brolene® on the adherence of *Candida albicans* to human buccal epithelial cells and on hyphal development in vitro (105) 71
Jones, D.S. and Shaffer, K.N.
The effects of tobramycin, amiloride, sodium cholate and sodium deoxycholate on the growth inhibitory activity of ciprofloxacin against a respiratory tract isolate of *Pseudomonas aeruginosa* (101) R7
Jones, D.S., see Schep, L.J. (105) 39
Jones, H.P., Clements, R., Hearn, D.J. and Gamlen, M.J.
Development and application of a pharmacokinetic simulation program for oral controlled release dosage forms – DIPS (104) 253
Jordan, C.G.M., see Quigley, J.M. (101) 145
Jørgensen, K., see Bertelsen, P. (111) 117
Jørgensen, L. and Bechgaard, E.
Intranasal permeation of thyrotropin-releasing hormone: in vitro study of permeation and enzymatic degradation (107) 231
Jørgensen, L., see Bechgaard, E. (106) 237
Josefson, M., see Gottfries, J. (106) 141

Jürjenson, H., see Sirkiä, T. (107) 179
Jürjenson, H., see Veski, P. (111) 171
Justel, A., see Del Estal, J.L. (102) 257

Kadir, F., see Zuidema, J. (105) 189
Kagayama, A., see Hata, T. (110) 1
Kaka, I., see Shah, J.C. (109) 283
Kakee, A., Yamane, H., Nanayama, T., Hibi, T., Sugimori, K.-i., Handa, T. and Miyajima, K.
Structure and tumor necrosis factor-inducing activity of dispersed particles of a lipid A analogue, GLA-60, and phosphatidylcholine mixture (111) 15
Kanfer, I., see Tandt, L.A.G.L. (104) 11
Kararli, T.T., Farhadieh, B., Bittner, S., Babler, M., Yang, P.-C. and Walsh, G.M.
Role of intestinal transport and first pass liver extraction on oral delivery of renin inhibitor compounds (102) 177
Karidas, T., see Malamataris, S. (103) 205
Karidas, T., see Malamataris, S. (104) 115
Karlsen, J., see Henriksen, I. (101) 227
Katayama, N., Houjou, T. and Takada, K.
Lymphatic transport of cyclosporin A from the abdominal cavity (110) 155
Katikaneni, P.R., see Upadrashta, S.M. (112) 173
Kawashima, Y., see Morishima, K. (105) 11
Kawashima, Y., see Morishima, K. (105) 11
Kearney, A.S., Gabriel, D.L., Mehta, S.C. and Radebaugh, G.W.
Effect of polyvinylpyrrolidone on the crystallinity and dissolution rate of solid dispersions of the antiinflammatory CI-987 (104) 169
Kearney, A.S., Mehta, S.C. and Radebaugh, G.W.
Preformulation studies to aid in the development of an injectable formulation of PD 144872, a radiosensitizing anticancer agent (102) 63
Kearney, M., see Niven, R.W. (101) 81
Kellaway, I.W., see Davies, N.M. (105) 97
Kellaway, I.W., see García González, N. (104) 107
Kennedy, R.A., see Padmadisastra, Y. (104) R1
Kennedy, R.A., see Padmadisastra, Y. (112) 55
Kenyon, C.J., Cole, E.T. and Wilding, I.R.
The effect of food on the in vivo behaviour of enteric coated starch capsules (112) 207
Kerč, J., see Gašperlin, M. (107) 51
Kesselring, U.W., see Ruelle, P. (104) 125
Khan, M.A., Bolton, S. and Kislalioglu, M.S.
Optimization of process variables for the preparation of ibuprofen coprecipitates with Eudragit S100 (102) 185
Khotz, M.S., see Vervaet, C. (106) 157
Kikuchi, H., see Maruyama, K. (111) 103
Kikuchi, R., see Watanabe, Y. (110) 93
Kim, C.-K., Choi, J.-Y., Yoon, Y.-S., Gong, J.-P., Choi, H.-G., Kong, J.Y. and Lee, B.-J.
Preparation and evaluation of a dry elixir for the enhancement of the dissolution rate of poorly water-soluble drugs (106) 25
Kim, C.-K., Im, E.-B., Lim, S.-J., Oh, Y.-K. and Han, S.-K.
Development of glucose-triggered pH-sensitive liposomes for a potential insulin delivery (101) 191
Kim, C.-K., Kim, M.-J. and Oh, K.-H.
Preparation and evaluation of sustained release microspheres of terbutaline sulfate (106) 213
Kim, C.-K., Lee, M.-K., Han, J.-H. and Lee, B.-J.
Pharmacokinetics and tissue distribution of methotrexate after intravenous injection of differently charged liposome-entrapped methotrexate to rats (108) 21
Kim, C.-K., see Jeong, Y.N. (102) 35
Kim, M.-J., see Kim, C.-K. (106) 213
Kim, S.R., see Doherty, M.M. (111) 205
Kim, S.W., see Cremers, H.F.M. (110) 117
Kim, W.B., see Shim, H.J. (103) 147
Kim, W.B., see Yoon, E.J. (109) 181
Kinget, R. and De Greef, H.
Absorption characteristics of novel 8-MOP semi-solid-lipid-matrix formulations: In vitro-in vivo correlation (110) 65
Kinget, R., see Van den Mooter, G. (111) 127
Kinnunen, P., see Murtoniemi, E. (108) 155
Kinnunen, P., see Murtoniemi, E. (110) 101
Kiriyama, M., see Watanabe, Y. (110) 93
Kishimoto, S.-i., see Takada, K. (101) 89
Kislalioglu, M.S., see Khan, M.A. (102) 185
Kitamura, S., Chang, L.-C. and Guillory, J.K.
Polymorphism of mefloquine hydrochloride (101) 127
Kivinen, A., Vikholm, I. and Tarpila, S.
A film balance study of the monolayer-forming properties of dietary phospholipids and the interaction with NSAIDs on the monolayers (108) 109
Klang, S., see Zeevi, A. (108) 57
Kleinebudde, P.
Shrinking and swelling properties of pellets containing microcrystalline cellulose and low substituted hydroxypropylcellulose: I. Shrinking properties (109) 209
Kleinebudde, P.
Shrinking and swelling properties of pellets containing microcrystalline cellulose and low substituted hydroxypropylcellulose: II. Swelling properties (109) 221
Kleinebudde, P., see Bleich, J. (106) 77
Klimmek, R., see Thiermann, H. (109) 35
Knepp, W.A., see Jayakrishnan, A. (106) 221
Koch, M.H.J., see Westesen, K. (103) 225
Kochhar, S.K., Rubinstein, M.H. and Barnes, D.
Slugging and recompression characterisation of some blends of pharmaceutical excipients (112) 225
Komai, T., see Tokui, T. (110) 277
Kong, J.Y., see Kim, C.-K. (106) 25
Konstantinov, C., see Atcheva, M. (103) 303
Kramer, P.A., see Lamson, M.J. (105) 259
Kreuter, J., see Borchard, G. (110) 29
Kreuter, J., see Langer, K. (110) 21
Kreuter, J., see Ruland, A. (101) 57
Kreuter, J., see Ruland, A. (103) 77

Kreuter, J., see Ruland, A. (107) 23
Kreuter, J., see Scherer, D. (101) 165
Kreuter, J., see Zimmer, A.K. (110) 211
Kristensen, S., see Tønnesen, H.H. (110) 161
Kristl, J., see Gašperlin, M. (107) 51
Kubo, H., Hosoya, K.-i., Natsume, H., Sugibayashi, K. and Morimoto, Y.
In vitro permeation of several model drugs across rabbit nasal mucosa (103) 27
Kubo, K., see Yoshimura, Y. (103) 1
Kwon, G., see Cremers, H.F.M. (110) 117
Kwong, E.C., Lamarche, P.L., Down, G.R.B., McClintock, S.A., Vadas, E.B. and Cotton, M.L.
Formulation assessment of MK-886, a poorly water-soluble drug, in the beagle dog (103) 259

Lam, K., see Cremers, H.F.M. (110) 117
La Manna, A., see Ferrari, F. (109) 115
Lamarche, P., see Cotton, M.L. (109) 237
Lamarche, P.L., see Kwong, E.C. (103) 259
Lammers, J.-W.J., see Zanen, P. (107) 211
Lamont, G., see Washington, N. (108) 125
Lamson, M.J., Herbette, L.G., Peters, K.R., Carson, J.H., Morgan, F., Chester, D.C. and Kramer, P.A.
Effects of hexagonal phase induction by dolichol on phospholipid membrane permeability and morphology (105) 259
Lan, E.-L., see Ugwu, S.O. (102) 193
Lancaster, J., see Adjei, A. (107) 57
Landau, I., see Mbela, T.K.M.N. (110) 189
Landín, M., Martínez-Pacheco, R., Gómez-Amoza, J.L., Souto, C., Concheiro, A. and Rowe, R.C.
Dicalcium phosphate dihydrate for direct compression: Characterization and intermanufacturer variability (109) 1
Landín, M., Martínez-Pacheco, R., Gómez-Amoza, J.L., Souto, C., Concheiro, A. and Rowe, R.C.
The effect of country of origin on the properties of dicalcium phosphate dihydrate powder (103) 9
Landín, M., Pérez-Marcos, B., Casalderrey, M., Martínez-Pacheco, R., Gómez-Amoza, J.L., Souto, C., Concheiro, A. and Rowe, R.C.
Chemical stability of acetylsalicylic acid in tablets prepared with different commercial brands of dicalcium phosphate dihydrate (107) 247
Landín, M., Rowe, R.C. and York, P.
Particle size effects on the dehydration of dicalcium phosphate dihydrate powders (104) 271
Langer, K., Seegmüller, E., Zimmer, A. and Kreuter, J.
Characterisation of polybutylcyanoacrylate nanoparticles: I. Quantification of PBCA polymer and dextrans (110) 21
Lanzarotti, E., see Ahmed, S.M. (109) 99
Lashmar, U.T. and Manger, J.
Investigation into the potential for iontophoresis facilitated transdermal delivery of acyclovir (111) 73
Lashmar, U.T., Provasi, D. and Poole, S.W.
Evaluation of the delivery of suspensions from an ultrasonic nebuliser with and without the lung surfactant 'Exosurf' (103) 119
Lastra, C.F., see Modamio, P. (107) 243
Lastra, C.F., see Modamio, P. (112) 93
Lau, S.W.J., see Shah, J.C. (109) 283
Lauroba, J., see Calpena, A.C. (103) 179
Law, S.L., Jang, T.F., Chang, P. and Lin, C.H.
Release characteristics of mitoxantrone-containing liposomes (103) 81
Lawrence, C.B., see Aboofazeli, R. (111) 63
Lawrence, M.J., see Aboofazeli, R. (106) 51
Lawrence, M.J., see Aboofazeli, R. (111) 63
Lawter, J.R., see Touitou, E. (104) 19
Lazar, J.D., see Thombre, A.G. (111) 181
Lebegue, S., see Gressier, B. (104) 151
Le Corre, P., Le Guevello, P., Gajan, V., Chevanne, F. and Le Verge, R.
Preparation and characterization of bupivacaine-loaded polylactide and polylactide-co-glycolide microspheres (107) 41
Lee, B.-J., see Kim, C.-K. (106) 25
Lee, B.-J., see Kim, C.-K. (108) 21
Lee, E.D., see Shim, H.J. (103) 147
Lee, E.D., see Yoon, E.J. (109) 181
Lee, H.J., see Yoon, W.H. (102) 249
Lee, H.K., see Hume, L.R. (111) 295
Lee, K.C., Song, H.M., Oh, I.J. and DeLuca, P.P.
Reversed-phase high-performance liquid chromatography for simultaneous determination of prostaglandins E_2, A_2 and B_2 (106) 167
Lee, K.C., see Oh, I.J. (106) 135
Lee, M.-K., see Kim, C.-K. (108) 21
Lee, M.G., see Francomb, M.M. (103) 87
Lee, M.G., see Jeong, Y.N. (102) 35
Lee, M.G., see Shim, H.J. (103) 147
Lee, M.G., see Yoon, E.J. (109) 181
Lee, M.G., see Yoon, W.H. (102) 249
Lee, S.D., see Shim, H.J. (103) 147
Lee, S.D., see Yoon, E.J. (109) 181
Lee, S.H., see Jeong, Y.N. (102) 35
Lee, S.H., see Yoon, W.H. (102) 249
Lefebvre, R.A., see De Muynck, C. (104) 1
Lefebvre, R.A., see De Muynck, C. (104) 87
Le Guevello, P., see Le Corre, P. (107) 41
Leharne, S., see Buckton, G. (110) 179
Lehtola, V.-M., see Heinämäki, J.T. (112) 191
Leiviskä, K., see Merkku, P. (102) 117
Leiviskä, K., see Murtoniemi, E. (108) 155
Leiviskä, K., see Murtoniemi, E. (110) 101
León, M.J., see Lucero, M.J. (106) 125
León, M.J., see Lucero, M.J. (110) 241
León, M.J., see Lucero, M.J. (111) 261
Le Ray, A.M., Vert, M., Gautier, J.C. and Benoît, J.P.
Fate of [^{14}C]poly(DL-lactide-co-glycolide) nanoparticles after intravenous and oral administration to mice (106) 201
Lerk, C.F., see Te Wierik, G.H.P. (102) 81

Lerk, C.F., see Zuurman, K. (102) 1
Leroy-Lechat, F., Wouessidjewe, D., Andreux, J.-P., Puisieux, F. and Duchêne, D.
Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives (101) 97
Leuenberger, H., see Bausch, A. (101) 63
Leuenberger, H., see Caraballo, I. (109) 229
Le Verge, R., see Le Corre, P. (107) 41
Levi-Schaffer, F., see Touitou, E. (103) 131
Lévy, M.-C., see Edwards-Lévy, F. (103) 253
Lilley, J.C., Patterson, L.H. and Taylor, M.J.
Preparation and stability of liposome encapsulated doxorubicin and mitoxantrone and their internalisation by murine peritoneal macrophages (107) 149
Lim, S.-J., see Kim, C.-K. (101) 191
Lin, C.H., see Law, S.L. (103) 81
Lin, H.-H., Huang, Y.-B., Hsu, L.-R. and Tsai, Y.-H.
The influence of process-induced variations on the nature of stearic acid incorporation into an FAPG base (112) 165
Lin, M.-C. and Duncan-Hewitt, W.C.
Deformation kinetics of acetaminophen crystals (106) 187
Lin, S.-Z., Wouessidjewe, D., Poelman, M.-C. and Duchêne, D.
In vivo evaluation of indomethacin/cyclodextrin complexes Gastrointestinal tolerance and dermal anti-inflammatory activity (106) 63
Lin, T., see Adjei, A. (107) 57
Lindqvist, A.-S., see Merkku, P. (102) 117
Li Wan Po, A., see Jian, L. (107) 77
Li Wan Po, A., see McCallion, R. (105) 103
Lloyd, A.W., Martin, G.P. and Soozandehfar, S.H.
Azopolymers: a means of colon specific drug delivery? (106) 255
Loftsson, T., Friðriksdóttir, H., Sigurðardóttir, A.M. and Ueda, H.
The effect of water-soluble polymers on drug-cyclodextrin complexation (110) 169
Loftsson, T., Friðriksdóttir, H., Thórisdóttir, S. and Stefánsson, E.
The effect of hydroxypropyl methylcellulose on the release of dexamethasone from aqueous 2-hydroxypropyl-β-cyclodextrin formulations (104) 181
Lordi, N.G., see Jerzewski, R.L. (101) 35
Lordi, N.G., see Jerzewski, R.L. (101) 45
Los, G., see Cremers, H.F.M. (110) 117
Lott, F.D., see Niven, R.W. (101) 81
Lötter, A.P., see Müller, D.G. (102) 109
Lovell, M.W., Johnson, H.W., Hui, H.-W., Cannon, J.B., Gupta, P.K. and Hsu, C.C.
Less-painful emulsion formulations for intravenous administration of clarithromycin (109) 45
Low, A.S., see Taylor, R.B. (102) 201
Lu, M.-Y.F., see Powers, M.E. (108) 49
Lu, S.M. and Yu, J.-Y.
Dimensionless presentation for drug release from a coated pure drug bead: 2. Experiment (112) 117
Lu, S.M.
Dimensionless presentation for drug release from a coated pure drug bead: 1. Analysis (112) 105
Lubbers, S.C.M., see Van der Houwen, O.A.G.J. (112) 97
Lucero, M.J., Sánchez, J.A., Vigo, J., Martín, F. and Rabasco, A.M.
Protection by α-tocopherol against skin ulcers induced by ionizing radiations (104) 49
Lucero, M.J., Vigo, J. and León, M.J.
A study of shear and compression deformations on hydrophilic gels of α-tocopherol (111) 261
Lucero, M.J., Vigo, J. and León, M.J.
A study of shear and compression deformations on hydrophilic gels of tretinoin (106) 125
Lucero, M.J., Vigo, J. and León, M.J.
Stability of hydrophilic geis of tretinoin (110) 241
Ludwig, A., see Mbela, T.K.M.N. (110) 189
Lund, E.M., see Østberg, T. (112) 241
Lundberg, B.
The solubilization of lipophilic derivatives of podophyllotoxins in sub-micron sized lipid emulsions and their cytotoxic activity against cancer cells in culture (109) 73
Lunghetti, G., see Pitcairn, G. (102) 11
Luyckx, M., see Benaji, B. (105) 83
Luyckx, M., see Faouzi, M.A. (105) 89
Luyckx, M., see Gressier, B. (104) 151
Lydén, M., see Aldén, M. (110) 267
Lynch, S., see Hastewell, J. (101) 115

Machida, Y., see Muramatsu, K. (107) 1
Machida, Y., see Ohara, N. (105) 31
Macías Sánchez, B., Martinez Cabarga, M., Sánchez Navarro, A. and Dominguez-Gil Hurlé, A.
A physico-chemical study of the interaction of ciprofloxacin and ofloxacin with polivalent cations (106) 229
Mackay, M., see Hastewell, J. (101) 115
Mackellar, A.J., Buckton, G., Newton, J.M. and Orr, C.A.
The controlled crystallisation of a model powder: 2. Investigation into the mechanism of action of poloxamers in changing crystal properties (112) 79
Mackellar, A.J., Buckton, G., Newton, J.M., Chowdhry, B.Z. and Orr, C.A.
The controlled crystallisation of a model powder: 1. The effects of altering the stirring rate and the supersaturation profile, and the incorporation of a surfactant (Poloxamer 188) (112) 65
Maffione, G., see Gazzaniga, A. (108) 77
Maganti, L. and Çelik, M.
Compaction studies on pellets: II. Coated pellets (103) 55
Magnusson, C., see Toth, I. (102) 223
Maibach, H.I., see Patil, S.M. (110) 147
Maibach, H.I., see Quan, D. (104) 61
Maibach, H.I., see Singh, P. (101) R1
Maincent, P., see Zimmer, A.K. (110) 211
Mainwaring, D.E., see Doherty, M.M. (111) 205
Maitani, Y., see Muramatsu, K. (107) 1

Malamataris, S. and Karidas, T.
Effect of particle size and sorbed moisture on the tensile strength of some tableted hydroxypropyl methylcellulose (HPMC) polymers (104) 115
Malamataris, S., Karidas, T. and Goidas, P.
Effect of particle size and sorbed moisture on the compression behaviour of some hydroxypropyl methylcellulose (HPMC) polymers (103) 205
Malick, A.W., see Shah, N.H. (106) 15
Mallevais, M.L., see Benaji, B. (105) 83
Mallevais, M.L., see Faouzi, M.A. (105) 89
Mallinson, C.B., see Higginbottom, S. (109) 173
Manger, J., see Lashmar, U.T. (111) 73
Mannermaa, J.P., Räisänen, J., Hyvönen-Dabek, M., Spring, E. and Yliruusi, J.
Use of proton-induced X-ray emission (PIXE) analysis in the evaluation of large volume parenteral rubber stoppers (103) 125
Manning, M.C., see Powers, M.E. (108) 49
Mannova, M., see Engel, A. (107) 99
Marcello, J., see Smith, P.L. (106) 95
Margarit, M.V., Rodríguez, I.C. and Cerezo, A.
Physical characteristics and dissolution kinetics of solid dispersions of ketoprofen and polyethylene glycol 6000 (108) 101
Mariño, E.L., see Modamio, P. (107) 243
Mariño, E.L., see Modamio, P. (112) 93
Marriott, C., see Timsina, M.P. (101) 1
Marriott, C., see Zeng, X.M. (107) 205
Marriott, C., see Zeng, X.M. (109) 135
Martín, F., see Lucero, M.J. (104) 49
Martin, G.P., see Lloyd, A.W. (106) 255
Martin, G.P., see Timsina, M.P. (101) 1
Martin, G.P., see Zeng, X.M. (107) 205
Martin, G.P., see Zeng, X.M. (109) 135
Martínez-Pacheco, R., see Landín, M. (103) 9
Martínez-Pacheco, R., see Landín, M. (107) 247
Martínez-Pacheco, R., see Landín, M. (109) 1
Martinez Cabarga, M., see Macías Sánchez, B. (106) 229
Marty, J.P., see Ferreira, L.A.M. (109) 251
Maruyama, K., Okuizumi, S., Ishida, O., Yamauchi, H., Kikuchi, H. and Iwatsuru, M.
Phosphatidyl polyglycerols prolong liposome circulation in vivo (111) 103
Maruyama, K., see Watanabe, Y. (110) 93
Marvola, M., see Sirkiä, T. (107) 179
Marvola, M., see Veski, P. (111) 171
Massart, L., see Vervaet, C. (106) 157
Masse, J., see El Moussaoui, A. (106) 109
Matar, S., see Touitou, E. (103) 199
Matsumoto, K., Nakai, Y., Yonemochi, E., Oguchi, T. and Yamamoto, K.
Physicochemical characteristics of porous crystalline cellulose and formation of an amorphous state of ethenzamide by mixing (108) 167
Matsumoto, M., see Watanabe, Y. (110) 93
Matsumoto, Y., see Watanabe, Y. (110) 93
Mazzeo, P., see Carlucci, G. (102) 271
Mazzone, G., see Bonina, F.P. (106) 115
Mazzone, G., see Castelli, F. (103) 217
Mbela, T.K.M.N., Ludwig, A., Landau, I., Deharo, E. and Haemers, A.
Preparation, characterization and in vivo activity of mefloquine submicron emulsions (110) 189
McCallion, R. and Li Wan Po, A.
Modelling transepidermal water loss under steady-state and non-steady-state relative humidities (105) 103
McCarthy, D.E., see Jani, P.U. (105) 157
McClintock, S.A., see Kwong, E.C. (103) 259
McCormack, B. and Gregoriadis, G.
Drugs-in-cyclodextrins-in liposomes: a novel concept in drug delivery (112) 249
McGinity, J.W., see Gutiérrez-Rocca, J.C. (103) 293
McGinity, J.W., see Jenquin, M.R. (101) 23
McKeown, R.H., see Prankerd, R.J. (112) 1
McKillop, A.G., see Rowe, R.C. (101) 169
Mehta, S.C., see Hauss, D.J. (108) 85
Mehta, S.C., see Kearney, A.S. (102) 63
Mehta, S.C., see Kearney, A.S. (104) 169
Melia, C.D., see Watts, P.J. (102) 101
Menegatti, E., see Cortesi, R. (105) 181
Merino, V., see Garrigues, T.M. (101) 209
Merino, V., see Segura-Bono, M.J. (107) 159
Merkku, P., Lindqvist, A.-S., Leiviskä, K. and Yliruusi, J.
Influence of granulation and compression process variables on flow rate of granules and on tablet properties, with special reference to weight variation (102) 117
Merkku, P., see Murtoniemi, E. (108) 155
Merkku, P., see Murtoniemi, E. (110) 101
Mesiha, M., Plakogiannis, F. and Vejosoth, S.
Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsions (111) 213
Michniak, B.B., Player, M.R., Fuhrman, L.C., Christensen, C.A., Chapman, Jr, J.M. and Srto, J.W.S.
In vitro evaluation of a series of Azone analogs as dermal penetration enhancers: III. Acyclic amides (110) 231
Miller, J., see Gochoco, C.H. (104) 187
Mitchell, A.G., see El-Bagory, I. (105) 255
Mitra, A.K., see Fort, J.J. (102) 241
Mitra, A.K., see Fort, J.J. (107) 9
Mitra, A.K., see Shao, Z. (112) 181
Mittelman, S.D., see Niven, R.W. (109) 17
Miyajima, K., see Kakee, A. (111) 15
Miyamoto, M., see Yoshimura, Y. (103) 1
Mizuno, N., see Motozono, H. (108) 39
Modamio, P., Lastra, C.F. and Mariño, E.L.
Determination of celiprolol by high-performance liquid chromatography and stability in solution (107) 243
Modamio, P., Montejo, O., Lastra, C.F. and Mariño, E.L.
A valid high-performance liquid chromatography method for oxprenolol stability studies (112) 93
Moës, A.J., see Beten, D.B. (103) 243
Moltrasio, D., see Ahmed, S.M. (109) 99
Monedero Perales, M.C., see Muñoz-Ruiz, A. (110) 37

Monedero Perales, M.C., see Velasco Antequera, M.V. (103) 155
Mönkkönen, J., Valjakka, R., Hakasalo, M. and Urtti, A.
The effects of liposome surface charge and size on the intracellular delivery of clodronate and gallium in vitro (107) 189
Montassier, P., see Amdidouche, D. (111) 111
Montejo, O., see Modamio, P. (112) 93
Montenegro, L., see Bonina, F.P. (102) 19
Montenegro, L., see Bonina, F.P. (106) 115
Montenegro, L., see Bonina, F.P. (111) 191
Moore, D.E., see Zhou, W. (110) 55
Móra, M., see Pató, J. (104) 227
Morel, S., Gasco, M.R. and Cavalli, R.
Incorporation in lipospheres of [D-Trp-6]LHRH (105) R1
Morgan, F., see Lamson, M.J. (105) 259
Morimoto, Y., see Kubo, H. (103) 27
Morishima, K., Kawashima, Y., Takeuchi, H., Niwa, T., Hino, T. and Kawashima, Y.
Tabletting properties of bucillamine agglomerates prepared by the spherical crystallization technique (105) 11
Morita, E., see Motozono, H. (108) 39
Mørk, N., see Thomsen, K.F. (112) 143
Morris, K.R., Fakes, M.G., Thakur, A.B., Newman, A.W., Singh, A.K., Venit, J.J., Spagnuolo, C.J. and Serajuddin, A.T.M.
An integrated approach to the selection of optimal salt form for a new drug candidate (105) 209
Morris, K.R., Newman, A.W., Bugay, D.E., Ranadive, S.A., Singh, A.K., Szyper, M., Varia, S.A., Brittain, H.G. and Serajuddin, A.T.M.
Characterization of humidity-dependent changes in crystal properties of a new HMG-CoA reductase inhibitor in support of its dosage form development (108) 195
Morsing, T., see Gottfries, J. (106) 141
Motola, S., see Cotton, M.L. (109) 237
Motozono, H., Mizuno, N., Morita, E., Fujioka, Y. and Takahashi, K.
Effect of age on gastrointestinal absorption of tobramycin in rats (108) 39
Müller, B.W., see Bleich, J. (106) 77
Müller, B.W., see Holzner, P.M. (106) 69
Müller, B.W., see Reer, O. (104) 239
Müller, D.G., Stella, V.J. and Lötter, A.P.
Determination of the position of the ester bond in a micellar prodrug of phenytoin (102) 109
Müller, D.G., see Du Plessis, J. (103) 277
Müller, D.G., see Du Plessis, J. (103) R1
Müller, R.H. and Heinemann, S.
Fat emulsions for parenteral nutrition. IV. Lipofundin MCT/LCT regimens for total parenteral nutrition (TPN) with high electrolyte load (107) 121
Müller, R.H. and Heinemann, S.
Fat emulsions for parenteral nutrition. III: Lipofundin MCT/LCT regimens for total parenteral nutrition (TPN) with low electrolyte load (101) 175
Muñoz-Ruiz, A., Payán Villar, T., Muñoz Muñoz, N., Monedero Perales, M.C. and Jiménez-Castellanos, M.R.
Analysis of the physical characterization and the tabletability of calcium phosphate-based materials (110) 37
Muñoz Muñoz, N., see Muñoz-Ruiz, A. (110) 37
Muñoz Muñoz, N., see Velasco Antequera, M.V. (103) 155
Muñoz Ruiz, A., see Velasco Antequera, M.V. (103) 155
Muramatsu, K., Maitani, Y., Machida, Y. and Nagai, T.
Effect of soybean-derived sterol and its glucoside mixtures on the stability of dipalmitoylphosphatidylcholine and dipalmitoylphosphatidylcholine/cholesterol liposomes (107) 1
Murtoniemi, E., Merkku, P., Kinnunen, P., Leiviskä, K. and Yliruusi, J.
Effect of neural network topology and training end point in modelling the fluidized bed granulation process (110) 101
Murtoniemi, E., Yliruusi, J., Kinnunen, P., Merkku, P. and Leiviskä, K.
The advantages by the use of neural networks in modelling the fluidized bed granulation process (108) 155
Musa, R., see Steed, K.P. (112) 199

Nadai, T., see Yamashita, S. (108) 241
Nagai, T., see Muramatsu, K. (107) 1
Nagai, T., see Ohara, N. (105) 31
Naggi, A., see Ahmed, S.M. (109) 99
Naisbett, B. and Woodley, J.
The potential use of tomato lectin for oral drug delivery. 1. Lectin binding to rat small intestine in vitro (107) 223
Naisbett, B. and Woodley, J.
The potential use of tomato lectin for oral drug delivery: 2. Mechanism of uptake in vitro (110) 127
Naisbett, B., see Pató, J. (104) 227
Naka, T., see Yoshimura, Y. (103) 1
Nakahigashi, Y., see Takada, K. (101) 89
Nakai, Y., see Matsumoto, K. (108) 167
Nanayama, T., see Kakee, A. (111) 15
Nankervis, R., Davis, S.S., Day, N.H. and Shaw, P.N.
Studies on the intravenous pharmacokinetics of three retinoids in the rat (101) 249
Naon, R., see Privitera, N. (104) 41
Narisawa, S., Yoshino, H., Hirakawa, Y. and Noda, K.
Porosity-controlled ethylcellulose film coating. II. Spontaneous porous film formation in the spraying process and its solute permeability (104) 95
Nastruzzi, C., see Cortesi, R. (105) 181
Natsume, H., see Kubo, H. (103) 27
Neau, S.H., Chow, M.Y. and Chafetz, L.
The influence of reaction conditions on the derivatization of carbidopa by β-dicarbonyl compounds for enhanced optical rotation (108) 95
Neau, S.H., see Upadrashta, S.M. (112) 173
Némati, F., Dubernet, C., De Verdière, A.C., Poupon, M.F., Treupel-Acar, L., Puisieux, F. and Couvreur, P.
Some parameters influencing cytotoxicity of free doxoru-

bicin and doxorubicin-loaded nanoparticles in sensitive and multidrug resistant leucemic murine cells: incubation time, number of nanoparticles per cell (102) 55
Newman, A.W., see Morris, K.R. (105) 209
Newman, A.W., see Morris, K.R. (108) 195
Newman, S., see Pitcairn, G. (102) 11
Newman, S.P., Hollingworth, A. and Clark, A.R.
Effect of different modes of inhalation on drug delivery from a dry powder inhaler (102) 127
Newton, J.M., see Chawla, A. (108) 233
Newton, J.M., see Mackellar, A.J. (112) 65
Newton, J.M., see Mackellar, A.J. (112) 79
Newton, J.M., see Sutananta, W. (110) 75
Newton, J.M., see Sutananta, W. (111) 51
Nguyen, F., see Peyrot, M. (102) 25
Nguyen, T.H., see Wilke, T.L. (103) 187
Nicholls, D., see Walker, I. (104) 157
Nicholls, D., see Walker, I. (108) 225
Nielsen, L.S., Sløk, F. and Bundgaard, H.
N-Alkoxycarbonyl prodrugs of mebendazole with increased water solubility (102) 231
Nielsen, L.S.
Improved peroral bioavailability of mebendazole in rabbits by administration of various *N*-alkoxycarbonyl derivatives of mebendazole (104) 175
Nikupaavo, P., see Heinämäki, J.T. (112) 191
Nimier, K., Robic, D. and Bourbouze, R.
Macromolecular aggregation of F1 and P1 fractions of RU 41740 an immunomodulating compound isolated from *Klebsiella pneumoniae*, as revealed by size exclusion high-performance liquid chromatography and light scattering detection (105) 235
Nishihata, T., see Yamamoto, K. (102) 133
Nishikawa, K., see Yoshimura, Y. (103) 1
Nishikawa, M., see Takakura, Y. (105) 19
Niu, S., see Zhang, J. (101) 15
Niven, R.W. and Brain, J.D.
Some functional aspects of air-jet nebulizers (104) 73
Niven, R.W., Ip, A.Y., Mittelman, S.D., Farrar, C., Arakawa, T. and Prestrelski, S.J.
Protein nebulization: I. Stability of lactate dehydrogenase and recombinant granulocyte-colony stimulating factor to air-jet nebulization (109) 17
Niven, R.W., Lott, F.D., Ip, A.Y., Somaratne, K.D. and Kearney, M.
Development and use of an in vitro system to evaluate inhaler devices (101) 81
Niwa, K., see Takaya, T. (110) 47
Niwa, T., see Morishima, K. (105) 11
Noda, K., see Narisawa, S. (104) 95
Noguchi, A., see Ogiso, T. (102) 141
Nolen III, H.W., Catz, P. and Friend, D.R.
Percutaneous penetration of methyl phosphonate antisense oligonucleotides (107) 169
Nomura, H., see Watanabe, Y. (110) 93
Nordström, A.J., see Heinämäki, J.T. (109) 9
Nuhn, P., see Engel, A. (107) 99
Nyska, A., see Hoffman, A. (111) 197
Nyström, C., see Ek, R. (111) 43
Nyström, C., see Elamin, A.A. (111) 159

Obach, R., see Calpena, A.C. (103) 179
O'Driscoll, C.M., see O'Reilly, J.R. (105) 137
O'Driscoll, C.M., see O'Reilly, J.R. (109) 147
Ogiso, T., Iwaki, M., Jing-ping, Z., Tanino, T. and Noguchi, A.
Percutaneous absorption of betahistine through rat skin and pharmacokinetic analysis of the plasma concentration (102) 141
Oguchi, T., see Matsumoto, K. (108) 167
Oh, I.J., Song, H.M. and Lee, K.C.
Effect of 2-hydroxypropyl-β-cyclodextrin on the stability of prostaglandin E_2 in solution (106) 135
Oh, I.J., see Lee, K.C. (106) 167
Oh, K.-H., see Kim, C.-K. (106) 213
Oh, Y.-K., see Kim, C.-K. (101) 191
O'Hagan, D.T., Jeffery, H. and Davis, S.S.
The preparation and characterization of poly(lactide-co-glycolide) microparticles: III. Microparticle/polymer degradation rates and the in vitro release of a model protein (103) 37
O'Hagan, D.T., Rahman, D., Jeffery, H., Sharif, S. and Challacombe, S.J.
Controlled release microparticles for oral immunization (108) 133
O'Hagan, D.T., see Jenkins, P.G. (102) 261
Ohara, N., Takayama, K., Machida, Y. and Nagai, T.
Combined effect of *d*-limonene and temperature on the skin permeation of ketoprofen (105) 31
Ohta, N., see Chen, D. (106) 249
Okuizumi, S., see Maruyama, K. (111) 103
Oliva, M., see Coderch, L. (111) 7
O'Reilly, J.R., Corrigan, O.I. and O'Driscoll, C.M.
The effect of mixed micellar systems, bile salt/fatty acids, on the solubility and intestinal absorption of clofazimine (B663) in the anaesthetised rat (109) 147
O'Reilly, J.R., Corrigan, O.I. and O'Driscoll, C.M.
The effect of simple micellar systems on the solubility and intestinal absorption of clofazimine (B663) in the anaesthetised rat (105) 137
Ören, İ., see Şener, E. (110) 109
Orner, D., see Smith, P.L. (106) 95
Orr, C.A., see Mackellar, A.J. (112) 65
Orr, C.A., see Mackellar, A.J. (112) 79
Østberg, T. and Graffner, C.
Calcium alginate matrices for oral multiple unit administration: III. Influence of calcium concentration, amount of drug added and alginate characteristics on drug release (111) 271
Østberg, T., Lund, E.M. and Graffner, C.
Calcium alginate matrices for oral multiple unit administration: IV. Release characteristics in different media (112) 241
Otero-Espinar, F.J., see Ganza-Gonzalez, A. (106) 179

Otero Espinar, F.J., see García González, N. (104) 107
Ouriemchi, E.M., Bouzon, J. and Vergnaud, J.M.
Oral dosage forms with a core and shell with the same polymer containing different drug concentrations (102) 47
Oussoren, C., see Zuidema, J. (105) 189

Padmadisastra, Y., Kennedy, R.A. and Stewart, P.J.
Influence of carrier moisture adsorption capacity on the degree of adhesion of interactive mixtures (104) R1
Padmadisastra, Y., Kennedy, R.A. and Stewart, P.J.
Solid bridge formation in sulphonamide-Emdex interactive systems (112) 55
Paeratakul, O., see Bodmeier, R. (103) 47
Palazzo, S., see Giammona, G. (105) 57
Pande, G.S. and Shangraw, R.F.
Characterization of β-cyclodextrin for direct compression tableting (101) 71
Panduranga Rao, K., see Thacharodi, D. (111) 235
Park, J.M., see Yoon, W.H. (102) 249
Parra, J.L., see Coderch, L. (111) 7
Patel, C.I., see Shah, N.H. (106) 15
Patel, N.K., Upadhyay, A.H., Bergum, J.S. and Reier, G.E.
An evaluation of microcrystalline cellulose and lactose excipients using an instrumented single station tablet press (110) 203
Patel, N.R., see Sinko, P.J. (109) 125
Patil, S.M., Singh, P. and Maibach, H.I.
Cumulative irritancy in man to sodium lauryl sulfate: The overlap phenomenon (110) 147
Pató, J., Móra, M., Naisbett, B., Woodley, J.F. and Duncan, R.
Uptake and transport of poly(*N*-vinylpyrrolidone-co-maleic acid) by the adult rat small intestine cultured in vitro: effect of chemical structure (104) 227
Patterson, L.H., see Lilley, J.C. (107) 149
Pavliv, L., Freebern, K., Wilke, T., Chiang, C.-C., Shetty, B. and Tyle, P.
Topical formulation development of a novel thymidylate synthase inhibitor for the treatment of psoriasis (105) 227
Payán Villar, T., see Muñoz-Ruiz, A. (110) 37
Pellett, M.A., Davis, A.F. and Hadgraft, J.
Effect of supersaturation on membrane transport: 2. Piroxicam (111) 1
Peppas, N.A., see Hariharan, D. (112) 47
Perez-Marcos, B., Ford, J.L., Amstrong, D.J., Elliott, P.N.C., Rostron, C. and Hogan, J.E.
Release of propranolol hydrochloride from matrix tablets containing hydroxypropylmethylcellulose K4M and carbopol 974 (111) 251
Pérez-Marcos, B., see Landín, M. (107) 247
Pes, M.A., see García-Celma, M.J. (105) 77
Peters, K.R., see Lamson, M.J. (105) 259
Petiprez, S., see Fournier, C. (106) 41
Pettersson, A., see Gottfries, J. (106) 141
Peyrot, M., Sautereau, A.M., Rabanel, J.M., Nguyen, F., Tocanne, J.F. and Samain, D.
Supramolecular biovectors (SMBV): a new family of nanoparticulate drug delivery systems. Synthesis and structural characterization (102) 25
Phillips, E.M. and Byron, P.R.
Surfactant promoted crystal growth of micronized methylprednisolone in trichloromonofluoromethane (110) 9
Pinnamaraju, P., see Seth, S.C. (106) 7
Pinzauti, S., see Corti, P. (111) 83
Pitarresi, G., see Giammona, G. (105) 57
Pitcairn, G., Lunghetti, G., Ventura, P. and Newman, S.
A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler, at two inhaled flow rates (102) 11
Plá-Delfina, J.M., see Fabra-Campos, S. (109) 197
Plá-Delfina, J.M., see Garrigues, T.M. (101) 209
Plakogiannis, F., see Mesiha, M. (111) 213
Player, M.R., see Michniak, B.B. (110) 231
Pochopin, N.L., Charman, W.N. and Stella, V.J.
Kinetics of rearrangement and hydrolysis of amino acid derivatives of prazosin (105) 169
Poelman, M.-C., see Amdidouche, D. (111) 111
Poelman, M.-C., see Lin, S.-Z. (106) 63
Pons, L., see Coderch, L. (111) 7
Poole, S.W., see Lashmar, U.T. (103) 119
Popat, S.C., see Ho, A.H.L. (104) 247
Poupon, M.F., see Némati, F. (102) 55
Powers, M.E., Adjei, A., Lu, M.-Y.F. and Manning, M.C.
Solution behavior of leuprolide acetate, an LHRH agonist, as determined by circular dichroism spectroscopy (108) 49
Pozzi, F., see Wilding, I.R. (111) 99
Prankerd, R., see Beall, H. (111) 223
Prankerd, R.J. and McKeown, R.H.
Physico-chemical properties of barbituric acid derivatives: IV. Solubilities of 5,5-disubstituted barbituric acids in water (112) 1
Préat, V., see Thysman, S. (101) 105
Prestrelski, S.J., see Niven, R.W. (109) 17
Prieto, J.G., see Del Estal, J.L. (102) 257
Privitera, N., Naon, R. and Riess, J.G.
Phagocytosis by cultured mouse peritoneal macrophages of microspheres coated with perfluoroalkylated telomeric surfactants derived from tris(hydroxymethyl)aminomethane (104) 41
Provasi, D., see Lashmar, U.T. (103) 119
Pruvo, J.-P., see Fournier, C. (106) 41
Puech, A., see El Moussaoui, A. (106) 109
Pugh, W.J. and Hadgraft, J.
Ab initio prediction of human skin permeability coefficients (103) 163
Puglisi, G., see Castelli, F. (103) 217
Puglisi, G., see Cavallaro, G. (111) 31
Puisieux, F., see Blanco Prieto, M.J. (111) 137
Puisieux, F., see Clemessy, M. (101) 219
Puisieux, F., see Jansen, J. (103) 19
Puisieux, F., see Leroy-Lechat, F. (101) 97
Puisieux, F., see Némati, F. (102) 55
Puri, A., see Ho, A.H.L. (107) 199

Quan, D. and Maibach, H.I.
An electron spin resonance study: I. Effect of Azone® on 5-doxyl stearic acid-labeled human stratum corneum (104) 61
Quiding, H., see Gjellan, K. (102) 71
Quigley, J.M., Jordan, C.G.M. and Timoney, R.F.
The synthesis, hydrolysis kinetics and lipophilicity of *O*-acyl esters of propranolol (101) 145

Rabanel, J.M., see Peyrot, M. (102) 25
Rabasco, A.-M., see Fernández-Hervás, M.-J. (108) 187
Rabasco, A.M., see Caraballo, I. (109) 229
Rabasco, A.M., see Lucero, M.J. (104) 49
Radebaugh, G.W., see Hauss, D.J. (108) 85
Radebaugh, G.W., see Kearney, A.S. (102) 63
Radebaugh, G.W., see Kearney, A.S. (104) 169
Ragnarsson, G., see Davidson, R. (112) 153
Rahman, D., see O'Hagan, D.T. (108) 133
Räisänen, J., see Mannermaa, J.P. (103) 125
Ramachandran, C., see Du Plessis, J. (103) 277
Ranadive, S.A., see Morris, K.R. (108) 195
Reer, O. and Müller, B.W.
Determination of the degree of substitution of chemically modified cyclodextrins by a microcalorimetric titration technique (104) 239
Reid, B.D., see El-Bagory, I. (105) 255
Reier, G.E., see Patel, N.K. (110) 203
Remon, J.-P., see Vervaet, C. (106) 157
Remon, J.-P., see Vervaet, C. (107) 29
Remon, J.P., see De Muynck, C. (104) 1
Remon, J.P., see De Muynck, C. (104) 87
Remon, J.P., see Vervaet, C. (108) 207
Rhodes, C.T., see Jiménez-Castellanos, M.R. (105) 65
Riccieri, F., see Touitou, E. (103) 131
Richards, R.M.E., see Taylor, R.B. (102) 201
Riepma, K.A., see Zuurman, K. (102) 1
Riess, J.G., see Privitera, N. (104) 41
Riis, K.J., see Bechgaard, E. (106) 237
Risha, P.A., see Vervaet, C. (107) 29
Ritschel, W.A., see Turkoglu, M. (103) 115
Rivera, S.L. and Ghodbane, S.
In vitro adsorption-desorption of famotidine on microcrystalline cellulose (108) 31
Rizk, S., Duru, C., Gaudy, D., Jacob, M., Ferrari, F., Bertoni, M. and Caramella, C.
Physico-chemical characterization and tabletting properties of Scleroglucan (112) 125
Roberts, M.S., see Singh, P. (101) R1
Roberts, R.J. and Rowe, R.C.
The unit cell dimensions of (*R,S*)-propranolol hydrochloride – A confirmatory study using data from powder X-ray diffraction (109) 83
Roberts, R.J., Rowe, R.C. and York, P.
The Poisson's ratio of microcrystalline cellulose (105) 177
Robic, D., see Nimier, K. (105) 235
Robinson, J.R., see Calvo, P. (103) 283
Robinson, J.R., see Gupta, P.K. (109) 91
Robinson, J.R., see Scherer, D. (101) 165
Rochard, E., Barthes, D. and Courtois, P.
Stability and compatibility study of carboplatin with three portable infusion pump reservoirs (101) 257
Rodríguez, I.C., see Margarit, M.V. (108) 101
Rohr, U., see Ruland, A. (107) 23
Rollet, M., see Sébert, P. (110) 285
Rollet, M., see Sébert, P. (106) 103
Rostron, C., see Perez-Marcos, B. (111) 251
Rowe, R.C., McKillop, A.G. and Bray, D.
The effect of batch and source variation on the crystallinity of microcrystalline cellulose (101) 169
Rowe, R.C., see Hancock, B.C. (102) 167
Rowe, R.C., see Landín, M. (103) 9
Rowe, R.C., see Landín, M. (104) 271
Rowe, R.C., see Landín, M. (107) 247
Rowe, R.C., see Landín, M. (109) 1
Rowe, R.C., see Roberts, R.J. (105) 177
Rowe, R.C., see Roberts, R.J. (109) 83
Rowe, R.C., see Sakellariou, P. (102) 207
Rowe, R.C., see Ticehurst, M.D. (111) 241
Rowlings, C.E., see Upadrashta, S.M. (112) 173
Roy, S.D. and De Groot, J.S.
Percutaneous absorption of nafarelin acetate, an LHRH analog, through human cadaver skin and monkey skin (110) 137
Rubinstein, M.H., see Kochhar, S.K. (112) 225
Rubitski, B.A., see Desai, D.S. (103) 69
Rubitski, B.A., see Desai, D.S. (107) 141
Rubitski, B.A., see Desai, D.S. (110) 249
Rubitski, B.A., see Desai, D.S. (110) 257
Ruelle, P., Sarraf, E. and Kesselring, U.W.
Prediction of carbazole solubility and its dependence upon the solvent nature (104) 125
Ruland, A., Kreuter, J. and Rytting, J.H.
Transdermal delivery of the tetrapeptide Hisetal (melanotropin (6–9)): II. Effect of various penetration enhancers. In vitro study across human skin (103) 77
Ruland, A., Kreuter, J. and Rytting, J.H.
Transdermal delivery of the tetrapeptide hisetal (melanotropin (6–9)). I. Effect of various penetration enhancers: in vitro study across hairless mouse skin (101) 57
Ruland, A., Rohr, U. and Kreuter, J.
Transdermal delivery of the tetrapeptide Hisetal (melanotropin (6–9)) and amino acids: their contribution to the elucidation of the existence of an 'aqueous pore' pathway (107) 23
Ryan, F.M., see Gochoco, C.H. (104) 187
Rytting, J.H., see Ruland, A. (101) 57
Rytting, J.H., see Ruland, A. (103) 77

Saettone, M.F., see Chetoni, P. (105) 147
Sakellariou, P., Hassan, H. and Rowe, R.C.
Plasticization and interactions of polyethylene glycol 6000 with hydroxypropyl methylcellulose/polyvinyl alcohol blends (102) 207
Sakr, A., see Hutchings, D. (104) 203

Sakr, A., see Turkoglu, M. (103) 115
Saleki-Gerhardt, A., Ahlneck, C. and Zografi, G.
Assessment of disorder in crystalline solids (101) 237
Salomies, H.E.M., Heinonen, R.M. and Toppila, M.A.I.
Sorptive loss of diazepam, nitroglycerin and warfarin sodium to polypropylene-lined infusion bags (Softbags) (110) 197
Salonen, H., see Sirkiä, T. (107) 179
Sam, A.P., see Untema, K. (112) 215
Samain, D., see Peyrot, M. (102) 25
Samyn, C., see Van den Mooter, G. (111) 127
Sánchez, J.A., see Lucero, M.J. (104) 49
Sánchez Navarro, A., see Macías Sánchez, B. (106) 229
Sanchis-Cortés, A., see Fabra-Campos, S. (109) 197
Sangalli, M.E., see Gazzaniga, A. (108) 77
Sanzgiri, Y.D., Topp, E.M., Benedetti, L. and Stella, V.J.
Evaluation of mucoadhesive properties of hyaluronic acid benzyl esters (107) 91
Sanzgiri, Y.D., see Hume, L.R. (111) 295
Sarraf, E., see Ruelle, P. (104) 125
Sautereau, A.M., see Peyrot, M. (102) 25
Sautou, V., Chopineau, J., Gremeau, I., Chevrier, R. and Bruneaux, F.
Compatibility with medical plastics and stability of continuously and simultaneously infused isosorbide dinitrate and heparin (107) 111
Schara, M., see Gabrijelčič, V. (102) 151
Schep, G.P., see Schep, L.J. (105) 39
Schep, L.J., Jones, D.S., Schep, G.P. and Shepherd, M.G.
A method to study the adherence of *Candida albicans* to human buccal epithelial cells in vitro using $^{35}SO_4$ radiolabelled blastospores and a Percoll™ gradient (105) 39
Scherer, D., Robinson, J.R. and Kreuter, J.
Influence of enzymes on the stability of polybutylcyanoacrylate nanoparticles (101) 165
Sébert, P., Bourny, E., Benghalem, A., Vergnaud, J.M. and Rollet, M.
Modelling of release kinetics of drugs from irradiated NaCMC matrix (110) 285
Sébert, P., Bourny, E. and Rollet, M.
Gamma irradiation of carboxymethylcellulose: technological and pharmaceutical aspects (106) 103
Sebhatu, T., Angberg, M. and Ahlneck, C.
Assessment of the degree of disorder in crystalline solids by isothermal microcalorimetry (104) 135
Seegmüller, E., see Langer, K. (110) 21
Segura-Bono, M.J., Garrigues, T.M., Merino, V. and Bermejo, M.V.
Compared effects of synthetic and natural bile acid surfactants on xenobiotic absorption. III. studies with mixed micelles (107) 159
Segura-Bono, M.J., see Garrigues, T.M. (101) 209
Seiller, M., see Ferreira, L.A.M. (109) 251
Şener, E., Turgut, H., Yalçın, İ., Ören, İ., Türker, L., Çelebi, N. and Akın, A.
Structure-activity relationships of some antimicrobial 5-substituted 2-(3-pyridyl)benzoxazoles using quantum-chemical calculations (110) 109
Šentjurc, M., see Gabrijelčič, V. (102) 151
Serajuddin, A.T.M., see Morris, K.R. (105) 209
Serajuddin, A.T.M., see Morris, K.R. (108) 195
Seth, S.C., Allen, Jr, L.V. and Pinnamaraju, P.
Stability of hydrocortisone salts during iontophoresis (106) 7
Seymour, L.W., see Cremers, H.F.M. (110) 117
Sezaki, H., see Takakura, Y. (105) 19
Sforzini, B.V., see Thomsen, K.F. (112) 143
Shaffer, K.N., see Jones, D.S. (101) R7
Shah, A.C., see Yamamoto, K. (102) 133
Shah, J.C., Kaka, I., Tenjarla, S., Lau, S.W.J. and Chow, D.
Analysis of percutaneous permeation data: II. Evaluation of the lag time method (109) 283
Shah, K.P. and Chafetz, L.
Use of sparingly soluble salts to prepare oral sustained release suspensions (109) 271
Shah, N.H., Carvajal, M.T., Patel, C.I., Infeld, M.H. and Malick, A.W.
Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs (106) 15
Shangraw, R.F., see Pande, G.S. (101) 71
Shao, Z., Hoffman, A.J. and Mitra, A.K.
Biodegradation characteristics of acyclovir 2'-esters by respiratory carboxylesterases: Implications in prodrug design for intranasal and pulmonary drug delivery (112) 181
Sharif, S., see O'Hagan, D.T. (108) 133
Sharma, S., see Ugwu, S.O. (102) 193
Shaw, P.N., see Nankervis, R. (101) 249
Shepherd, M.G., see Schep, L.J. (105) 39
Sheridan, P.L., Buckton, G. and Storey, D.E.
The extent of errors associated with contact angles. II. Factors affecting data obtained using a Wilhelmy plate technique for powders (109) 155
Shetty, B., see Pavliv, L. (105) 227
Sheu, M.-T., Yeh, C.-M. and Sokoloski, T.D.
Characterization and dissolution of fenofibrate solid dispersion systems (103) 137
Shi, F., see Borchard, G. (110) 29
Shim, H.J., Lee, E.D., Yoon, E.J., Lee, S.D., Kim, W.B., Yang, J. and Lee, M.G.
Pharmacokinetics of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM or FT-ADM to rats. A new adriamycin analog containing fluorine (103) 147
Shim, H.J., see Yoon, E.J. (109) 181
Shimazaki, Y., see Hata, T. (110) 1
Short, M.D., see Barker, S.A. (102) 159
Sigurðardóttir, A.M., see Loftsson, T. (110) 169
Simamora, P., see Surakitbanharn, Y. (109) 27
Simeonova, M., see Atcheva, M. (103) 303
Singh, A.K., see Morris, K.R. (105) 209
Singh, A.K., see Morris, K.R. (108) 195
Singh, P., Guy, R.H., Roberts, M.S. and Maibach, H.I.
What is the transport-limiting barrier in iontophoresis? (101) R1
Singh, P., see Patil, S.M. (110) 147

Singla, A.K. and Wadhwa, H.
Zinc-aspirin complex:synthesis, physicochemical and biological evaluation (108) 173
Sinko, P.J., Patel, N.R. and Hu, P.
Site-specific oral absorption of didanosine: in situ characterization and correlation with extent of absorption in vivo (109) 125
Sirkiä, T., Salonen, H., Veski, P., Jürjenson, H. and Marvola, M.
Biopharmaceutical evaluation of new prolonged-release press-coated ibuprofen tablets containing sodium alginate to adjust drug release (107) 179
Skelton-Stroud, P., see Hastewell, J. (101) 115
Sloan, K., see Beall, H. (111) 223
Sløk, F., see Nielsen, L.S. (102) 231
Smal, J., see Veski, P. (111) 171
Šmid-Korbar, J., see Gašperlin, M. (107) 51
Smistad, G., see Henriksen, I. (101) 227
Smith, P.L., Marcello, J., Chiossone, D.C., Orner, D. and Hidalgo, I.J.
Absorption of an RGD peptide (SK&F 106760) following intratracheal administration in rats (106) 95
Smith, P.L., see Gochoco, C.H. (104) 187
Sokoloski, T.D., see Sheu, M.-T. (103) 137
Solans, C., see García-Celma, M.J. (105) 77
Somaratne, K.D., see Niven, R.W. (101) 81
Song, H.M., see Lee, K.C. (106) 167
Song, H.M., see Oh, I.J. (106) 135
Soozandehfar, S.H., see Lloyd, A.W. (106) 255
Souto, C., see Landín, M. (103) 9
Souto, C., see Landín, M. (107) 247
Souto, C., see Landín, M. (109) 1
Spagnuolo, C.J., see Morris, K.R. (105) 209
Sparrow, R.A., see Wilding, I.R. (101) 263
Spöhrer, U., see Thiermann, H. (109) 35
Spring, E., see Mannermaa, J.P. (103) 125
Spring, M.S., see Femi-Oyewo, M.N. (112) 17
Srinivasan, V., see Inamori, T. (105) 113
Srto, J.W.S., see Michniak, B.B. (110) 231
Stanley, T.H., see Zhang, J. (101) 15
Steed, K.P., Hooper, G., Ventura, P., Musa, R. and Wilding, I.R.
The in vivo behaviour of a colonic delivery system: a pilot study in man (112) 199
Steed, K.P., see Wilding, I.R. (101) 263
Stefánsson, E., see Loftsson, T. (104) 181
Stella, V.J., see Antipas, A.S. (109) 261
Stella, V.J., see Hume, L.R. (111) 295
Stella, V.J., see Müller, D.G. (102) 109
Stella, V.J., see Pochopin, N.L. (105) 169
Stella, V.J., see Sanzgiri, Y.D. (107) 91
Sternberg, B., see Yoshioka, T. (105) 1
Steward, A., Bayley, D.L. and Howes, C.
The effect of enhancers on the buccal absorption of hybrid (BDBB) α-interferon (104) 145
Stewart, P.J., see Padmadisastra, Y. (104) R1
Stewart, P.J., see Padmadisastra, Y. (112) 55
Storey, D.E., see Sheridan, P.L. (109) 155
Strid, S., see Gjellan, K. (102) 213
Strøm, F., see Thomsen, K.F. (112) 143
Stubbs, C., see Tandt, L.A.G.L. (104) 11
Suda, Y., see Yamashita, S. (108) 241
Sugden, J.K., see Ho, A.H.L. (104) 247
Sugden, J.K., see Ho, A.H.L. (107) 199
Sugibayashi, K., see Kubo, H. (103) 27
Sugimori, K.-i., see Kakee, A. (111) 15
Sumi, M., see Yamashita, S. (108) 241
Surakitbanharn, Y., Simamora, P., Ward, G.H. and Yalkowsky, S.H.
Precipitation of pH solubilized phenytoin (109) 27
Suriol, M., see Calpena, A.C. (103) 179
Sutananta, W., Craig, D.Q.M. and Newton, J.M.
An investigation into the effect of preparation conditions on the structure and mechanical properties of pharmaceutical glyceride bases (110) 75
Sutananta, W., Craig, D.Q.M. and Newton, J.M.
The effects of ageing on the thermal behaviour and mechanical properties of pharmaceutical glycerides (111) 51
Szyper, M., see Morris, K.R. (108) 195

Tabatabay, C., see Bernatchez, S.F. (106) 161
Tada, N., see Yoshimura, Y. (103) 1
Takada, K., Nakahigashi, Y., Tanaka, T., Kishimoto, S.-i., Ushirogawa, Y. and Takaya, T.
Pharmacological activity of tablets containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats (101) 89
Takada, K., see Katayama, N. (110) 155
Takada, K., see Takaya, T. (110) 47
Takahashi, K., see Motozono, H. (108) 39
Takakura, Y., Fujita, T., Furitsu, H., Nishikawa, M., Sezaki, H. and Hashida, M.
Pharmacokinetics of succinylated proteins and dextran sulfate in mice: Implications for hepatic targeting of protein drugs by direct succinylation via scavenger receptors (105) 19
Takaya, T., Niwa, K. and Takada, K.
Pharmacological effect of recombinant human colony-stimulating factor (rhG-CSF) after administration into rat large intestine (110) 47
Takaya, T., see Takada, K. (101) 89
Takayama, K., see Ohara, N. (105) 31
Takeuchi, H., see Morishima, K. (105) 11
Tamura, S., see Hata, T. (110) 1
Tanaka, T., see Takada, K. (101) 89
Tandt, L.A.G.L., Stubbs, C. and Kanfer, I.
The use of dissolution rate data to account for differences in the absorption profiles of two controlled/modified-release capsule dosage forms of indomethacin in human volunteers (104) 11
Tanino, T., see Ogiso, T. (102) 141
Tanira, M.O.M., Wasfi, I.A., Bashir, A.K. and Harron, D.W.G.
Chronic verapamil administration alters phenytoin pharmacokinetics in the rat (102) 267

Tanzawa, K., see Tokui, T. (110) 277
Tarpila, S., see Kivinen, A. (108) 109
Tartar, A., see Blanco Prieto, M.J. (111) 137
Tasset, C., see Thysman, S. (101) 105
Taylor, G., see Davies, N.M. (105) 97
Taylor, K.M.G., see Ah-Fat, N.M.W. (107) 239
Taylor, K.M.G., see Barker, S.A. (102) 159
Taylor, K.M.G., see Chawla, A. (108) 233
Taylor, M.J., see Lilley, J.C. (107) 149
Taylor, R.B., Richards, R.M.E., Low, A.S. and Hardie, L.
Chemical stability of polymyxin B in aqueous solution (102) 201
Teeuwsen, J., see Van der Houwen, O.A.G.J. (105) 249
Tegenfeldt, J., see Aldén, M. (110) 267
Tenjarla, S., see Shah, J.C. (109) 283
Te Wierik, G.H.P., Eissens, A.C. and Lerk, C.F.
Preparation, characterization and pharmaceutical application of linear dextrins: V. Study on the binding properties of amylodextrin, metastable amylodextrin and metastable amylose (102) 81
Thacharodi, D. and Panduranga Rao, K.
Transdermal absorption of nifedipine from microemulsions of lipophilic skin penetration enhancers (111) 235
Thakur, A.B., see Morris, K.R. (105) 209
Thiermann, H., Spöhrer, U., Klimmek, R. and Eyer, P.
Operational evaluation of wet/dry autoinjectors containing atropine in solution and powdered HI 6 or HLö 7 (109) 35
Thomas, C., see Calvo, P. (103) 283
Thomas, M., see Davies, N.M. (105) 97
Thomas, N.W., see Jenkins, P.G. (102) 261
Thombre, A.G., DeNoto, A.R., Falkner, F.C. and Lazar, J.D.
In vitro/in vivo correlations of sustained-release coated multiparticulate formulations of doxazosin (111) 181
Thompson, G., see Toth, I. (106) 85
Thomsen, K.F., Strøm, F., Sforzini, B.V., Begtrup, M. and Mørk, N.
Evaluation of phenyl carbamates of ethyl diamines as cyclization-activated prodrug forms for protecting phenols against first-pass metabolism (112) 143
Thórisdóttir, S., see Loftsson, T. (104) 181
Thouvenot, P., see Zimmer, A.K. (110) 211
Thysman, S., Tasset, C. and Préat, V.
Transdermal iontophoresis of fentanyl: delivery and mechanistic analysis (101) 105
Ticehurst, M.D., Rowe, R.C. and York, P.
Determination of the surface properties of two batches of salbutamol sulphate by inverse gas chromatography (111) 241
Timoney, R.F., see Quigley, J.M. (101) 145
Timsina, M.P., Martin, G.P., Marriott, C., Ganderton, D. and Yianneskis, M.
Drug delivery to the respiratory tract using dry powder inhalers (101) 1
Titulaer, H.A.C., see Zuidema, J. (105) 189
Tocanne, J.F., see Peyrot, M. (102) 25
Tokui, T., Tokui, Y., Ishigami, M., Tanzawa, K., Ikeda, T. and Komai, T.
Targeting of an antitumor agent, RS-1541 (palmitoylrhizoxin), via low-density lipoprotein receptor (110) 277
Tokui, Y., see Tokui, T. (110) 277
Tønnesen, H.H., Kristensen, S. and Grinberg, L.N.
Studies on curcumin and curcuminoids: XXV. Inhibition of primaquine-induced lysis of human red blood cells by curcumin (110) 161
Topp, E.M., see Hume, L.R. (111) 295
Topp, E.M., see Sanzgiri, Y.D. (107) 91
Toppila, M.A.I., see Salomies, H.E.M. (110) 197
Torrado, J.J. and Augsburger, L.L.
Effect of different excipients on the tableting of coated particles (106) 149
Torri, G., see Ahmed, S.M. (109) 99
Torstensson, A., see Gottfries, J. (106) 141
Toth, I., Flinn, N., Hillery, A., Gibbons, W.A. and Artursson, P.
Lipidic conjugates of luteinizing hormone releasing hormone $(LHRH)^+$ and thyrotropin releasing hormone $(TRH)^+$ that release and protect the native hormones in homogenates of human intestinal epithelial (Caco-2) cells (105) 241
Toth, I., Hillery, A.M., Wood, I.P., Magnusson, C. and Artursson, P.
Oral absorption of lipidic amino acid conjugates (102) 223
Toth, I., Thompson, G. and Ward, P.
Lipophilic peptide inhibitors of ribonucleotide reductase enzyme of herpes simplex virus (106) 85
Touitou, E., Chow, D.D. and Lawter, J.R.
Chiral β-blockers for transdermal delivery (104) 19
Touitou, E., Deutsch, J. and Matar, S.
Iodine-polyurethane matrices: antimicrobial activity vs method of preparation (103) 199
Touitou, E., Levi-Schaffer, F., Dayan, N., Alhaique, F. and Riccieri, F.
Modulation of caffeine skin delivery by carrier design: liposomes versus permeation enhancers (103) 131
Treiner, C., see Jansen, J. (103) 19
Treupel-Acar, L., see Némati, F. (102) 55
Tsai, Y.-H., see Hsu, L.-R. (106) 1
Tsai, Y.-H., see Lin, H.-H. (112) 165
Tucker, S.A., see Acree, Jr, W.E. (101) 199
Tung, I.-C.
Rheological behavior of poloxamer 407 aqueous solutions during sol-gel and dehydration processes (107) 85
Turgut, H., see Şener, E. (110) 109
Türker, L., see Şener, E. (110) 109
Turkoglu, M., Ritschel, W.A. and Sakr, A.
In vivo evaluation of fluidized-bed coated pellets (103) 115
Tyle, P., see Pavliv, L. (105) 227
Tyle, P., see Wilke, T.L. (103) 187

Ueda, H., see Loftsson, T. (110) 169
Ueda, S., see Hata, T. (110) 1

Ugwu, S.O., Lan, E.-L., Sharma, S., Hruby, V. and Blanchard, J.
Kinetics of degradation of a cyclic lactam analog of α-melanotropin (MT-II) in aqueous solution (102) 193
Umapathi, P.
Determination of atenolol, nifedipine, aspirin and dipyridamole in tablet preparations by second-order derivative spectrophotometry (108) 11
Underberg, W.J.M., see Van der Houwen, O.A.G.J. (105) 249
Underberg, W.J.M., see Van der Houwen, O.A.G.J. (109) 191
Underberg, W.J.M., see Van der Houwen, O.A.G.J. (112) 97
Upadhyay, A.H., see Patel, N.K. (110) 203
Upadrashta, S.M., Katikaneni, P.R., Hileman, G.A., Neau, S.H. and Rowlings, C.E.
Compressibility and compactibility properties of ethylcellulose (112) 173
Upadrashta, S.M., see Goskonda, S.R. (111) 89
Urtti, A., see Mönkkönen, J. (107) 189
Ushirogawa, Y., see Takada, K. (101) 89

Vadas, E.B., see Cotton, M.L. (109) 237
Vadas, E.B., see Kwong, E.C. (103) 259
Valjakka, R., see Mönkkönen, J. (107) 189
Van Criekinge, W., see Van der Meeren, P. (106) 89
Van den Mooter, G., Samyn, C. and Kinget, R.
Characterization of colon-specific azo polymers: A study of the swelling properties and the permeability of isolated polymer films (111) 127
Vanderdeelen, J., see Van der Meeren, P. (106) 89
Van der Houwen, O.A.G.J., Beijnen, J.H., Bult, A. and Underberg, W.J.M.
A general approach to the interpretation of pH buffer catalyzed degradation profiles (109) 191
Van der Houwen, O.A.G.J., Bekers, O., Beijnen, J.H., Bult, A., Lubbers, S.C.M. and Underberg, W.J.M.
Degradation kinetics of the investigational antitumor compound LL-D49194α_1 in the presence of buffers (112) 97
Van der Houwen, O.A.G.J., Teeuwsen, J., Bekers, O., Beijnen, J.H., Bult, A. and Underberg, W.J.M.
Degradation kinetics of 7-*N*-(*p*-hydroxyphenyl)mitomycin C (M-83) in aqueous solution in the presence of γ-cyclodextrin (105) 249
Van der Meeren, P., Van Criekinge, W., Vanderdeelen, J. and Baert, L.
Phospholipid composition of r-DNA hepatitis B surface antigens (106) 89
Vander Velde, D., see Antipas, A.S. (109) 261
Van Vugt, M., see Cremers, H.F.M. (110) 117
Varia, S.A., see Desai, D.S. (103) 69
Varia, S.A., see Desai, D.S. (107) 141
Varia, S.A., see Desai, D.S. (110) 249
Varia, S.A., see Desai, D.S. (110) 257
Varia, S.A., see Morris, K.R. (108) 195
Vaution, C., see Jansen, J. (103) 19
Veiga, M.D. and De Eulate, J.A.
Dissolution study of spiramycin: influence of agitation intensity and addition of several substances to the dissolution medium (110) 223
Vejosoth, S., see Mesiha, M. (111) 213
Velasco Antequera, M.V., Muñoz Ruiz, A., Monedero Perales, M.C., Muñoz Muñoz, N. and Jiménez-Castellanos Ballesteros, M.R.
Evaluation of an adequate method of estimating flowability according to powder characteristics (103) 155
Venit, J.J., see Morris, K.R. (105) 209
Ventura, C., see Giammona, G. (105) 57
Ventura, P., see Pitcairn, G. (102) 11
Ventura, P., see Steed, K.P. (112) 199
Vergnaud, J.M., see Ouriemchi, E.M. (102) 47
Vergnaud, J.M., see Sébert, P. (110) 285
Vermeersch, H., see Vervaet, C. (106) 157
Vert, M., see Le Ray, A.M. (106) 201
Vervaet, C., Baert, L. and Remon, J.P.
Enhancement of in vitro drug release by using polyethylene glycol 400 and PEG-40 hydrogenated castor oil in pellets made by extrusion/spheronisation (108) 207
Vervaet, C., Baert, L., Risha, P.A. and Remon, J.-P.
The influence of the extrusion screen on pellet quality using an instrumented basket extruder (107) 29
Vervaet, C., Vermeersch, H., Khotz, M.S., Massart, L. and Remon, J.-P.
Parameters influencing granule quality using a continuous granulator (106) 157
Veski, P., Marvola, M., Smal, J., Heiskanen, I. and Jürjenson, H.
Biopharmaceutical evaluation of pseudoephedrine hydrochloride capsules containing different grades of sodium alginate (111) 171
Veski, P., see Sirkiä, T. (107) 179
Vetuschi, C., see Carlucci, G. (102) 271
Vigo, J., see Lucero, M.J. (104) 49
Vigo, J., see Lucero, M.J. (106) 125
Vigo, J., see Lucero, M.J. (110) 241
Vigo, J., see Lucero, M.J. (111) 261
Vikholm, I., see Kivinen, A. (108) 109
Vila-Jato, J.L., see Calvo, P. (103) 283
Vila-Jato, J.L., see Ganza-Gonzalez, A. (106) 179
Villari, A., see Cavallaro, G. (111) 31
Villaverde, C., see Del Estal, J.L. (102) 257
Vromans, H., see Zuurman, K. (102) 1

Wadhwa, H., see Singla, A.K. (108) 173
Walker, I., Nicholls, D., Irwin, W.J. and Freeman, S.
Drug delivery via active transport at the blood-brain barrier: II. Investigation of monocarboxylic acid transport in vitro (108) 225
Walker, I., Nicholls, D., Irwin, W.J. and Freeman, S.
Drug delivery via active transport at the blood-brain barrier: affinity of a prodrug of phosphonoformate for the large amino acid transporter (104) 157
Walsh, G.M., see Kararli, T.T. (102) 177
Wan, L.S.C., Heng, P.W.S. and Chan, L.W.
Surfactant effects on alginate microspheres (103) 267
Wannebroucq, J., see Fournier, C. (106) 41
Ward, G.H., see Surakitbanharn, Y. (109) 27
Ward, P., see Toth, I. (106) 85

Waring, M.J., see Ferrari, F. (112) 29
Wasfi, I.A., see Tanira, M.O.M. (102) 267
Washington, C., see Washington, N. (108) 125
Washington, N., Lamont, G., Wilson, C.G., Washington, C. and Withington, R.
The effect of high and low fat meals on the absorption of rifampicin from the gastrointestinal tract in volunteer subjects (108) 125
Watanabe, Y., Matsumoto, Y., Kikuchi, R., Kiriyama, M., Ito, R., Matsumoto, M., Nomura, H. and Maruyama, K.
Absorption and blood leukocyte dynamics of recombinant human granulocyte colony-stimulating factor (rhG-CSF) from intranasally administered preparations containing rhG-CSF and cyclodextrins in rabbits (110) 93
Watts, P.J., Wilson, C.G., Davies, M.C. and Melia, C.D.
Radiolabelling of polymer microspheres for scintigraphic investigations by neutron activation. 4. A pharmacoscintigraphic study of colon-targeted Eudragit RS-sulphapyridine microspheres in human volunteers (102) 101
Weiner, N., see Du Plessis, J. (103) 277
Weiner, N., see Du Plessis, J. (103) R1
Wepierre, J., see Ferreira, L.A.M. (109) 251
Westesen, K. and Koch, M.H.J.
Phase diagram of tyloxapol and water – II (103) 225
Westesen, K.
Phase diagram of tyloxapol and water – I (102) 91
Westrup, J., see Wilding, I.R. (101) 263
Whelan, I., see Burns, S.J. (110) 291
Wicks, S.R., see Aboofazeli, R. (111) 63
Wilding, I.R., Davis, S.S., Pozzi, F., Furlani, P. and Gazzaniga, A.
Enteric coated timed release systems for colonic targeting (111) 99
Wilding, I.R., Davis, S.S., Steed, K.P., Sparrow, R.A., Westrup, J. and Hempenstall, J.M.
Gastrointestinal transit of a drug-resinate administered as an oral suspension (101) 263
Wilding, I.R., see Kenyon, C.J. (112) 207
Wilding, I.R., see Steed, K.P. (112) 199
Wilhelm, F., see Engel, A. (107) 99
Wilke, T., see Pavliv, L. (105) 227
Wilke, T.L., Nguyen, T.H. and Tyle, P.
HPLC method development for AG-85 and benzyl alcohol in anhydrous topical formulations (103) 187
Williamson, I., see Hastewell, J. (101) 115
Wilson, C.G., see Washington, N. (108) 125
Wilson, C.G., see Watts, P.J. (102) 101
Winfield, A.J., see Cumming, K.I. (108) 141
Withington, R., see Washington, N. (108) 125
Won, C.M.
Kinetics and mechanism of hydrolysis of tyrphostins (104) 29
Wood, I.P., see Toth, I. (102) 223
Woodley, J., see Naisbett, B. (107) 223
Woodley, J., see Naisbett, B. (110) 127
Woodley, J.F., see Pató, J. (104) 227
Wouessidjewe, D., see Leroy-Lechat, F. (101) 97
Wouessidjewe, D., see Lin, S.-Z. (106) 63
Wu, P.-C., see Hsu, L.-R. (106) 1

Yalçın, İ., see Şener, E. (110) 109
Yalkowsky, S.H., see Surakitbanharn, Y. (109) 27
Yamamoto, K., Yokohama, S., Emori, H., Shah, A.C. and Nishihata, T.
Bioavailability of itazigrel in dogs after oral administration of soft elastic capsules (102) 133
Yamamoto, K., see Matsumoto, K. (108) 167
Yamane, H., see Kakee, A. (111) 15
Yamashita, S., Nadai, T., Sumi, M. and Suda, Y.
Possible role of serum protein binding to improve drug disposition (108) 241
Yamauchi, H., see Maruyama, K. (111) 103
Yang, J., see Shim, H.J. (103) 147
Yang, J., see Yoon, E.J. (109) 181
Yang, P.-C., see Kararli, T.T. (102) 177
Yazdanian, M.
The effect of freezing on cattle skin permeability (103) 93
Yeh, C.-M., see Sheu, M.-T. (103) 137
Yianneskis, M., see Timsina, M.P. (101) 1
Yliruusi, J., see Mannermaa, J.P. (103) 125
Yliruusi, J., see Merkku, P. (102) 117
Yliruusi, J., see Murtoniemi, E. (108) 155
Yliruusi, J., see Murtoniemi, E. (110) 101
Yliruusi, J.K., see Heinämäki, J.T. (109) 9
Yliruusi, J.K., see Heinämäki, J.T. (112) 191
Yokohama, S., see Yamamoto, K. (102) 133
Yonemochi, E., see Matsumoto, K. (108) 167
Yoon, E.J., Lee, E.D., Yoon, W.H., Shim, H.J., Lee, S.D., Kim, W.B., Yang, J. and Lee, M.G.
Pharmacokinetics, tissue distribution and biliary excretion of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM to dogs. A new adriamycin analog containing fluorine (109) 181
Yoon, E.J., see Shim, H.J. (103) 147
Yoon, E.J., see Yoon, W.H. (102) 249
Yoon, W.H., Yoon, E.J., Jang, S.H., Lee, S.H., Lee, H.J., Park, J.M., Choi, K.E. and Lee, M.G.
Pharmacokinetics of ciprofloxacin after intravenous administration of ciprofloxacin-TOF in rabbits (102) 249
Yoon, W.H., see Yoon, E.J. (109) 181
Yoon, Y.-S., see Kim, C.-K. (106) 25
York, P., see Agbada, C.O. (106) 33
York, P., see Hancock, B.C. (102) 167
York, P., see Landín, M. (104) 271
York, P., see Roberts, R.J. (105) 177
York, P., see Ticehurst, M.D. (111) 241
Yoshimura, Y., Tada, N., Kubo, K., Miyamoto, M., Inada, Y., Nishikawa, K. and Naka, T.
Evaluation and improvement of bioavailability of a new angiotensin II receptor antagonist, 2-butyl-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl-1H-benzimidazole-7-carboxylic acid by making prodrug (103) 1

Yoshino, H., see Narisawa, S. (104) 95
Yoshioka, T. and Florence, A.T.
Vesicle (niosome)-in-water-in-oil (v/w/o) emulsions: an in vitro study (108) 117
Yoshioka, T., Sternberg, B. and Florence, A.T.
Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85) (105) 1
Yotsuyanagi, T., see Chen, D. (106) 249
Yu, J.-Y., see Lu, S.M. (112) 117

Zanen, P., Go, L.T. and Lammers, J.-W.J.
The optimal particle size for β-adrenergic aerosols in mild asthmatics (107) 211
Zeevi, A., Klang, S., Alard, V., Brossard, F. and Benita, S.
The design and characterization of a positively charged submicron emulsion containing a sunscreen agent (108) 57
Zeng, X.M., Martin, G.P. and Marriott, C.
Albumin microspheres as a means of drug delivery to the lung: analysis of the effects of process variables on particle sizes using factorial design methodology (107) 205
Zeng, X.M., Martin, G.P. and Marriott, C.
Tetrandrine delivery to the lung: The optimisation of albumin microsphere preparation by central composite design (109) 135
Zhang, J., Niu, S., Ebert, C. and Stanley, T.H.
An in vivo dog model for studying recovery kinetics of the buccal mucosa permeation barrier after exposure to permeation enhancers: apparent evidence of effective enhancement without tissue damage (101) 15
Zheng, H. and Audus, K.L.
Cytotoxic effects of chlorhexidine and nystatin on cultured hamster buccal epithelial cells (101) 121
Zhou, W. and Moore, D.E.
Photochemical decomposition of sulfamethoxazole (110) 55
Zia, H., see Jiménez-Castellanos, M.R. (105) 65
Zimmer, A., see Langer, K. (110) 21
Zimmer, A.K., Maincent, P., Thouvenot, P. and Kreuter, J.
Hydrocortisone delivery to healthy and inflamed eyes using a micellar polysorbate 80 solution or albumin nanoparticles (110) 211
Zografi, G., see Saleki-Gerhardt, A. (101) 237
Zuidema, J., Kadir, F., Titulaer, H.A.C. and Oussoren, C.
Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II) (105) 189
Zuurman, K., Riepma, K.A., Bolhuis, G.K., Vromans, H. and Lerk, C.F.
The relationship between bulk density and compactibility of lactose granulations (102) 1

ELSEVIER

International Journal of Pharmaceutics 112 (1994) 291–305

international journal of pharmaceutics

Subject Index Vol. 101–112

Abamectin; (103) 93
Absorption; (101) R1; (105) 7; (105) 219; (106) 95; (111) 197
Absorption enhancement; (104) 1
Absorption enhancer; (104) 87; (104) 145
Absorption-partition correlation; (101) 209; (107) 159
Absorption rate; (102) 213; (105) 189
ACAT inhibitor; (108) 85
Ac-Di-Sol®; (110) 257
Acetaminophen; (106) 187
Acetylneurotensin 8–13; (112) 133
Acetylsalicylic acid; (107) 247
Acid-base catalysis; (109) 191
Acid-base interactions; (111) 241
Acrivastine; (104) 253
Actigall®; (109) 173
Activation; (108) 213
Activation energy; (106) 33; (106) 187
Activation volume; (106) 187
Active transport; (104) 157; (108) 225
Acyclovir; (111) 73; (112) 181
Additive effect; (112) 17
Adherence; (105) 71
Adherence assay; (105) 39
Adriamycin; (110) 117; (111) 25
Adsorption; (103) 87; (108) 31
Adsorption isotherm; (103) 19
Aerosol; (101) 81; (102) 159; (104) 73; (106) 69; (107) 211; (108) 233; (109) 17
Aerosol deposition; (102) 127
Aerosol formulation; (107) 57
Ag/AgCl electrode; (101) 219
Age; (108) 39
Agglomerate; (111) 43
Aggregation; (108) 49
Aggregometry; (105) 57
Air-jet nebulization; (109) 17
Albendazol; (102) 257
Albumin; (107) 205
Albumin microspheres; (106) 221; (109) 135
Albumin nanoparticles; (110) 211
Albuterol; (105) 147
Albuterol triester; (105) 147
Alginate; (111) 271; (112) 241
Alginate raft; (105) 97
N-Alkoxycarbonyl derivative; (102) 231; (104) 175
1-Alkyloxycarbonyl-5-fluorouracil; (111) 223
Alprenolol; (104) 19
Alumina particle; (103) 19
Aluminum tristearate; (106) 213
Amide; (110) 231
Amino acid; (105) 169; (111) 7
Amino acid transport; (104) 157
Aminoglycoside antibiotic; (108) 39
Amino group determination; (103) 253
Aminonaphthalene-3,6,8-trisulfonic acid; (101) 191
Amorphism; (108) 167
Amorphous material; (104) 135; (105) 125
Amylase; (101) 165
Amylodextrin; (102) 81
Analog; (102) 193
Angiotensin-converting enzyme; (107) 77; (112) 133
Angiotensin receptor antagonist; (103) 1
Anhydrous lactose; (110) 257
Anhydrous topical formulation; (103) 187
Animal model; (104) 1; (109) 45
Anisotropy; (111) 15
Antacid; (106) 229
Anthrone; (110) 21
Antibacterial activity; (110) 109
Antibody production; (103) 303
Anticancer; (102) 63
Anticancer drug; (108) 69; (111) 25
Antielastase activity; (104) 151
Anti-inflammatory activity; (106) 63; (108) 173
Antimicrobial activity; (103) 199
Antimycotic activity; (110) 109
Antioxidant; (104) 151; (107) 67; (110) 241
Antisense oligonucleotide; (107) 169
Antiulcerogenic activity; (108) 173
Apnoea; (103) 131
Aqueous coating; (104) 203
Aqueous colloidal polymer dispersion; (103) 47
Aqueous glycerol solution; (112) 117
Aqueous *N,N*-dimethylformamide mixture; (108) 149

Aqueous solution; (109) 191
Arginine salt; (105) 209
Aromatic amine; (105) 169
Arrhenius plot; (105) 31
Arterial embolization; (106) 41
Artificial neural network; (108) 155; (110) 101
Artificial throat; (101) 81
Ascorbic acid; (106) 125; (107) 199; (110) 241; (111) 261
Aspirin; (108) 11; (108) 173
Association constant; (101) 199
Atenolol; (104) 19; (108) 11
Atomizing air pressure; (102) 117
Atropine; (109) 35
Autoinjector, wet/dry; (109) 35
Automation method; (112) 37
Auto-oxidation; (111) 153
2,2′-Azobis(amidinopropane) dihydrochloride; (104) 247
2,2′-Azobis(2-amidinopropane) dihydrochloride; (107) 199
Azone®; (104) 61; (109) 283
Azone analog; (110) 231
Azone®; (101) 57; (103) 77; (110) 137
Azopolymer; (106) 255
Aztreonam; (110) 249

Barbiturate; (103) 19; (112) 1
Basket dissolution method; (112) 233
Basket extruder; (107) 29; (107) 219
Batch to batch variation; (111) 241
Bead formulation; (107) 141
Beagle dog; (103) 115
Beclomethasone dipropionate; (112) 199
Betahistine; (102) 141
Bilayer permeability; (105) 259
Bile salt; (101) 209; (103) 27; (105) 137; (107) 159; (109) 197; (111) 147
Biliary excretion; (109) 181
Binder amount; (102) 117
Binding agent; (106) 103
Binding properties; (102) 81
Bioadhesion; (104) 107; (105) 65; (107) 223; (110) 127
Bioavaibility; (110) 65
Bioavailability; (102) 71; (102) 213; (102) 257; (103) 1; (104) 11; (104) 87; (104) 145; (104) 175; (104) 215; (106) 161; (107) 179; (108) 39; (108) 125; (111) 171; (112) 87
Bioavailabilty; (102) 133
Biocompatibility; (110) 117
Biodegradable microparticles; (108) 133
Biodegradable microsphere; (111) 137
Biodegradable polymer; (106) 77
Biophysical model; (109) 197
Bioresorbable starch microsphere; (106) 41
Biphasic release; (110) 291
Blends; (102) 207
β-Blocker; (104) 19
Blood-brain barrier; (104) 157; (108) 225; (110) 29
Blood leukocyte count; (110) 93
Blood level; (110) 1
Blood partitioning; (103) 147
Blood pressure; (110) 1
Blood total leucocyte count; (101) 89
Blood total leukocyte count; (110) 47
BMS-180431; (105) 209
Bond formation process; (109) 59
Boroleucine; (105) 7
Bovine microvessel endothelial cell; (110) 29
Bovine serum albumin; (101) 63
Brain delivery; (104) 157; (108) 225
Brolene; (105) 71
Brush border membrane; (107) 223
Brush-border membrane; (111) 147
Buccal absorption; (104) 145; (105) 219
Buccal epithelial cell; (101) 121
Bucillamine; (105) 11
Buffer; (109) 27
Buffer-catalyzed degradation; (112) 97
Buffer effect; (109) 191
Bulk density; (102) 1
Bupivacaine; (107) 41
Burst release; (112) 105
BV-araU; (103) 69

Caco-2; (104) 187
Caco-2 cell culture model; (102) 223
Caco-2 cell homogenate; (105) 241
Cadaver skin; (110) 137
Caffeine; (103) 131; (111) 127; (112) 37
Calcium-induced gelation; (111) 271; (112) 241
Calcium phosphate-based material; (110) 37
Calorimetry; (105) 47; (110) 179
Cancer drug; (109) 73
Canderel; (107) 199
Candida albicans; (105) 39; (105) 71
Cannulation; (102) 261
Capillary interaction; (104) R1; (112) 55
Capsule formulation; (110) 249
Capsule size; (110) 249
Captopril; (107) 77
Carbamate; (112) 143
Carbazole; (104) 125
Carbidopa; (108) 95
Carbomer® 940; (106) 125; (110) 241; (111) 261
Carboplatin; (101) 257
Carbopol; (104) 107; (111) 251
Carboxyfluorescein; (105) 1; (111) 15
Carboxylesterase; (112) 181
Carboxypeptidase A; (107) 133
Carboxyvinyl polymer gel; (109) 115
κ-Carrageenan gel; (109) 115
Carteolol hydrochloride; (109) 229
Cascade impaction; (104) 73
Casein microspheres; (106) 221
Catalysis; (109) 191
Cathepsin B; (107) 133
Cattle skin; (103) 93

CD spectroscopy; (108) 49
Cefaclor; (111) 31
Cefsulodin; (111) 31
Celiprolol hydrochloride; (107) 243
Cell culture; (104) 157; (108) 225
Cell density; (101) 97
Cell proliferation; (103) 131
Cellulose acetate phthalate; (109) 9
Cellulose acetate trimellitate; (109) 9
Central composite design; (109) 135; (111) 271
Cephalexin; (104) 187
Cephalosporin; (104) 187
Cetrimide; (111) 73
Cetyltrimethylammonium bromide; (107) 239
Charged liposomes; (108) 21
Chemical stability; (107) 247
Chemometrics; (106) 141
Chemoprophylaxis; (103) 237
Chiral isomer; (104) 19
Chitosan; (101) 227; (111) 217
Chloramphenicol; (112) 241
Chlorhexidine; (101) 121
Cholesterol; (107) 1
Cholestyramine; (109) 107
Chylomicron; (108) 85
CI-987; (104) 169
Ciclopirox olamine; (105) 77
Cilia; (107) 77
Cineole; (105) 47
Ciprofloxacin; (101) R7; (102) 249; (106) 229
Ciprofloxacin-HCl; (102) 249
Ciprofloxacin-TOF; (102) 249
Circulation time; (111) 103
Clarithromycin; (109) 45
Clodronate; (107) 189
Clofazimine; (105) 137; (109) 147
Clotrimazole; (105) 77
Cloud point; (111) 251
Coated pellet; (103) 115
Coating; (106) 149; (111) 181
Codeine phosphate; (102) 71
Coevaporate; (103) 243
Colestipol; (109) 107
Colon delivery; (110) 47
Colonic delivery; (112) 199
Colonic drug delivery; (102) 101
Colonic specific delivery; (108) 77
Colon-specific drug delivery; (106) 255
Colon targeting; (111) 99
Colorimetric assay; (101) 121
Commercial formulation; (108) 11
Compactibility; (101) 71; (105) 11; (112) 173
Compaction; (102) 1; (103) 55; (109) 155; (112) 17
Compacts; (101) 35; (101) 45
Compatibility; (105) 83; (105) 89; (107) 111
Complexation; (110) 169
Compressibility; (112) 173
Compression; (103) 205; (104) 115
Compressional pressure; (106) 149
Compression coating; (107) 179
Compression deformation; (106) 125; (111) 261
Compression properties; (103) 9; (109) 1
Concentration/distance profile; (107) 9
Concurrent coating; (111) 117
Confocal microscopy; (107) 149
Conformation; (109) 261
Conscious rabbit; (110) 93
Consolidation; (102) 1
Consolidation mechanism; (110) 37
Contact angle; (109) 155; (112) 65
Container compatibility; (108) 1
Continuous granulation; (106) 157
Continuous infusion; (107) 111
Contour plot; (102) 185
Controlled atmosphere microbalance; (103) 103
Controlled drug release; (103) 47
Controlled release; (102) 47; (103) 243; (104) 95; (104) 253; (105) 181; (106) 221; (107) 41; (108) 133; (109) 229; (110) 117; (111) 89; (111) 197; (112) 215
Controlled release vaccine; (103) 37
Conway cell; (107) 141; (110) 257
Cooling rate; (112) 165
Coprecipitate; (102) 185
Core dosage form; (102) 47
Core-in-cup system; (112) 37
Corneal penetration; (103) 283
Corn starch; (110) 257
Cosolvency; (109) 291
Cosolvent; (103) 137
Cosurfactant; (106) 51; (111) 63
Countercurrent coating; (111) 117
Cremophor-EL; (105) 137
Critical micelle concentration; (108) 141
Crosslinking; (104) 107
Cross-linking; (111) 217
Cryo-electron microscopy; (101) 227
Crystal bridge; (104) R1
Crystal flow rate; (112) 17
Crystal growth; (110) 9
Crystal habit; (112) 17; (112) 65
Crystallinity; (101) 169; (104) 135; (104) 169; (105) 125; (111) 43
Crystallisation; (104) 135
Crystallization; (112) 65; (112) 79
Crystal properties; (108) 195; (112) 17
Crystal size; (112) 17
Crystal strength; (112) 17
Cumulative irritation; (110) 147
Cupric sulfate; (104) 247
Curcumin; (110) 161
Curing; (104) 203
Cyclization; (112) 143
Cyclodextrin; (101) 97; (104) 181; (104) 239; (105) 249; (110) 93; (110) 169; (112) 249

α-Cyclodextrin; (109) 99
β-Cyclodextrin; (101) 71; (106) 63; (106) 179; (111) 111
Cyclodextrin polymer; (112) 249
Cyclosporin; (103) 277
Cyclosporin A; (110) 155
Cytotoxic assay; (111) 25
Cytotoxicity; (101) 97; (101) 121; (102) 55

DA-125; (103) 147; (109) 181
Daunorubicin; (111) 25
Deactivation; (108) 213
Deamidation; (109) 261
Deformation kinetics; (106) 187
Degradation; (102) 193
Degradation kinetics; (105) 249; (109) 191; (112) 97
Degradation mechanism; (109) 237
Degree of disorder; (101) 237
Degree of substitution; (104) 239
Dehydration; (107) 85
Dehydration behavior; (103) 9; (104) 271; (109) 1
Dehydration kinetics; (106) 33
Delayed release; (108) 77
Delivery; (107) 189
Delivery kinetics; (102) 47
Deposition; (101) 81
Dequalinium chloride ferrous sulfate; (104) 247
Derivative UV spectrophotometry; (102) 271
Dermal delivery; (107) 169
Dermal/epidermal separation; (102) 241
Dermal homogenate; (102) 241
Dermal prodrug; (106) 115
Dermal route; (106) 63
Dermic gel; (111) 111
Desolvated emulsion; (111) 213
Desorption; (101) 23; (108) 31
Destolit®; (109) 173
Developmental intestinal function; (108) 39
Dexamethasone; (104) 181
Dexrazoxane; (107) 67
Dextran; (110) 21
Dextran sulfate; (105) 19
Dextrin; (106) 25
Dextropropoxyphene; (102) 213
Dextrose; (107) 199
cis-Diamminedichloroplatinum(II); (106) 249
Diazepam; (110) 197
Dibasic calcium phosphate; (112) 225
Dicalcium phosphate dihydrate; (103) 9; (104) 271; (107) 247; (109) 1
β-Dicarbonyl compound; (108) 95
Didanosine; (109) 125
Dietary protein; (101) 89
Dietary surfactant; (108) 109
Di(2-ethylhexyl) phthalate; (105) 89
Differential-pulse polarography; (111) 83
Diffusion; (101) 45; (106) 115; (109) 283; (111) 127
Diffusion apparatus; (101) 35
Diflunisal; (105) 57
Diltiazem; (109) 271
Dimer; (111) 153
Dimethylaminoisopropanol dodecanoate; (103) 77
Dioleoylphosphatidylcholine; (103) 81
Dipalmitoylphosphatidylcholine; (107) 1
Dipeptidyl peptidase II; (107) 133
Dipyridamole; (103) 243; (108) 11
Direct Compression; (101) 71
Direct compression; (103) 155; (105) 11; (109) 1; (112) 125
Direct compression excipient; (110) 37
Direct compression tableting; (110) 203
Direct current; (101) 219
Disaggregation; (109) 99
Disorder; (104) 135
Disordered surface layer thickness; (111) 159
Dissolution; (104) 107; (104) 169; (107) 141; (108) 167; (109) 221; (111) 251
Dissolution improvement; (110) 223
Dissolution kinetics; (108) 101
Dissolution medium composition; (110) 223
Dissolution profile; (110) 223
Dissolution rate; (104) 11; (104) 253
Dissolution rate enhancement; (108) 207
Dissolution stability; (110) 249; (110) 257
Dissolution testing; (102) 71; (104) 215; (106) 141; (111) 117; (112) 233
Distribution coefficient; (101) 145
Distribution study; (110) 211
Disulfide bond cleavage; (106) 249
DMSO; (105) 47
r-DNA vaccine; (106) 89
Dodecyl *N,N*-dimethylamino acetate; (101) 57; (103) 77
Dog; (109) 125; (112) 87
Dolichol; (105) 259
Domperidone; (103) 179
Dosage form design; (108) 195
Dose linearity; (107) 57
Double log-log model; (109) 291
Doxorubicin; (102) 55; (107) 67; (107) 149
Doxorubicin hydrochloride; (103) 87
5-Doxylstearic acid; (104) 61
Drug; (110) 169
Drug absorption; (105) 189
Drug administration; (111) 197
Drug carrier; (106) 201; (110) 127
Drug content; (103) 267
Drug damage; (104) 73
Drug degradation; (109) 237
Drug delivery; (101) 1; (102) 223; (105) 241; (108) 85; (109) 73; (111) 73; (111) 103
Drug delivery system; (102) 25; (102) 159; (105) 65; (108) 241; (110) 211
Drug disposition; (108) 241
Drug distribution; (108) 85
Drug entrapment; (109) 135; (112) 249
Drug fraction; (102) 71

Drug hydrate; (106) 33
Drug inclusion; (112) 215
Drug-polymer interaction; (101) 23
Drug release; (103) 267; (106) 149; (111) 283
Drug release equations; (112) 105
Drug release parameters; (112) 105
Drug-resinate; (101) 263
Drug targeting; (108) 85; (110) 117
Dry elixir; (106) 25
Dry powder inhaler; (101) 1; (101) 81; (102) 11; (108) 233
Dry skin; (105) 103
DSC; (102) 91; (102) 109; (103) 217; (104) 135; (106) 115; (107) 1; (107) 51; (108) 101; (108) 141; (110) 75; (110) 267; (111) 51; (111) 251; (112) 65; (112) 165

Econazole nitrate; (105) 77
EDTA; (102) 241
Elastic recovery; (103) 55
Elastic work; (112) 173
Electrical field; (105) 47
Electrochemical factors; (101) 105
Electro-osmosis; (101) 105
Electrophoretic light scattering; (101) 227
Electrophysiology; (103) 27; (106) 237
Electrotransport; (111) 73
Emulsion; (108) 85; (108) 117; (109) 45; (109) 73
Enalapril; (107) 77
Endocytosis; (110) 29; (110) 127
Endopeptidase-24.11; (112) 133
Enhancement; (101) R7
Enhancement action; (105) 31
Enhancer; (103) 179; (105) 219
Enteric coating; (110) 291; (111) 99; (112) 199; (112) 207
Enthalpy of dilution; (104) 239
Entrapment efficiency; (105) 1
Enzymatic cleavage; (105) 57
Enzymatic degradation; (107) 231
Enzyme degradation; (105) 241
Enzyme inhibitor; (107) 77
Epidermal homogenate; (102) 241
Epidermal thickness; (104) 49
EPR; (102) 151
Error; (109) 155
Erythropoietin; (111) 197
ESR; (104) 61
Esterase; (101) 165
Esterase activity; (102) 241
2'-Ester prodrug; (112) 181
Ethanol pretreated human epidermal membrane; (105) 113
Ethenzamide; (108) 167
Ethyl acetate; (101) 63
Ethyl cellulose; (103) 47
Ethylcellulose; (104) 95; (104) 203; (112) 37; (112) 173
Ethyl cellulose coating; (112) 117
Ethyl *p*-hydroxybenzoate; (112) 79
Ethyl vinyl acetate; (101) 257
Eudragit; (103) 243
Eudragit^{RL} copolymer; (103) 293
Eudragit RL; (101) 23
Eudragit RS; (101) 23; (102) 101
Eudragit RS®; (106) 213
Eudragit S100; (102) 185
Everted gut sac; (104) 227; (110) 127
Excipient evaluation; (110) 203
Expansion in water; (112) 153
Experimental design; (106) 141; (106) 157
Explotab®; (110) 257
Extended Hildebrand solubility approach; (108) 149
Extended release; (102) 185; (106) 141; (111) 271; (112) 241
Extended-release indomethacin; (104) 11
External beam proton-induced X-ray emission (PIXE) analysis; (103) 125
Extrusion; (107) 29; (107) 219; (111) 89
Extrusion force; (107) 219
Extrusion/spheronization; (109) 209; (109) 221

3^3 factorial design; (102) 117
Factorial design; (102) 185; (107) 205
Famotidine; (102) 271; (108) 31
FAPG base; (106) 1; (112) 165
Fast-Flo® lactose; (110) 257
Fat emulsion stability; (101) 175; (107) 121
Fatty acid; (104) 1; (104) 87; (106) 1; (109) 147
Fatty acid dispersion; (111) 213
Felodipine; (106) 141
Fenofibrate; (103) 137
Fentanyl; (101) 105
Fibroblast; (107) 189
Filler-binder; (101) 71
Film coating; (103) 47; (103) 69; (103) 293; (108) 77
Film dry matter quantity; (111) 117
Film porosity; (111) 117
Film thickness; (111) 117
First pass liver extraction; (102) 177
First-pass metabolism; (112) 143
FITC-dextran; (110) 21
FK409; (110) 1
Flotation; (105) 65
Flow; (103) 155
Flowability; (105) 11
Flowability index; (102) 185
Flow microcalorimetry; (111) 25
Flow rate; (102) 71; (103) 155; (104) 215
Flow-through cell; (103) 243
Flow-through dissolution method; (102) 71; (112) 233
Flow-through method; (104) 215
Fluid-bed drying; (109) 209; (109) 221
Fluidized bed; (103) 115
Fluidized bed granulation; (102) 117; (108) 155; (110) 101
Fluorescence anisotropy; (107) 1
Fluorescence depolarization; (102) 25
5-Fluorouracil; (106) 161; (108) 241
Flux; (110) 231
Food effect; (112) 87

Formaldehyde; (107) 141; (110) 257
Formulation; (109) 27
Formulation evaluation; (103) 259
Formulation stability; (109) 237
Fractal dimension; (108) 187
Fractal geometry; (108) 187
Fractals; (109) 155
Fraction of drug substance; (104) 215
Franz diffusion cell; (111) 111
Free film; (109) 9; (112) 191
Free radical; (104) 49
Freeze-drying; (107) 99; (109) 209; (109) 221
Freeze-fracturing; (102) 91
Freezing; (103) 93
Freundlich isotherm; (108) 31
Full-thickness skin; (107) 9
Furosemide; (111) 217

Galactocerebroside; (103) 81
Gallium; (107) 189
Gallstone dissolution; (109) 173
Gamma irradiation; (106) 103; (110) 285
Gamma scintigraphy; (101) 263; (102) 11; (102) 101; (102) 159; (105) 97; (108) 125; (111) 99; (112) 199; (112) 207
Gas density; (106) 77
Gastric emptying; (109) 91
Gastric mucosa; (107) 91
Gastric retention; (105) 97
Gastrointestinal absorption; (104) 253
Gastrointestinal tolerance; (106) 63
Gastrointestinal transit; (101) 263; (112) 199
Gastroprotection; (108) 109
GC; (110) 21
GC-headspace analysis; (103) 293
Gelatin microsphere; (105) 181
Gel chromatography; (108) 21
Gel formulation; (102) 19
Gel strength apparatus; (109) 115
Gelucire; (110) 75; (111) 51
General acid-base catalysis; (112) 97
Germination; (105) 71
GLA-60; (111) 15
Glass transition; (103) 293
Glass transition temperature; (108) 213
Glaucoma; (106) 161
Glucose oxidase; (101) 191
Glutaraldehyde crosslinking; (106) 221
Glyceride; (110) 75; (111) 51
Glycerol; (104) 107
Glycolipid; (107) 99
GM-1 ganglioside; (109) 99
Granulation; (102) 1
Granule flow rate; (102) 117
Granulocyte-colony stimulating factor; (109) 17
Granulocyte colony-stimulating factor; (110) 93
Grinding; (108) 167
Griseofulvin; (110) 267

Growth inhibition; (101) R7

Habit; (112) 79
Hairless mouse; (110) 231
Hairless mouse skin; (101) 57; (102) 241
Hairless mouse skin simulation; (107) 9
HALO™ drug delivery system; (110) 291
Hard gelatin capsule; (110) 291; (111) 171
Heat denaturation; (106) 41
Heat of crystallization; (101) 237
Heat separation; (102) 241
Heavy metal; (111) 153
Heckel equation; (103) 55
Heckel plot; (112) 173
Heparin; (107) 111
Heparin sodium salt; (102) 19; (111) 191
Hepatic targeting; (105) 19
Hepatitis B surface antigen; (106) 89
Herpesvirus ribonucleotide reductase inhibition; (106) 85
n-Hexane; (101) 63
HI 6; (109) 35
High-sensitivity DSC; (112) 65
High-viscosity HPMC; (108) 77
H&K 120; (110) 249
HLB; (105) 1
HLö 7; (109) 35
HMG-CoA reductase inhibitor; (105) 209; (108) 195
Homologous series; (102) 241
Hot-stage microscopy; (110) 75
L-HPC; (109) 209; (109) 221
H_{II} phase; (105) 259
HPLC; (102) 201; (103) 187; (105) 89; (106) 161; (106) 167; (107) 243; (110) 197; (112) 93
Human; (104) 87; (109) 125
Human bioavailability study; (110) 1
Human γ-globulin; (106) 249
Human plasma; (111) 83
Human serum albumin; (103) 253
Human skin; (103) 77; (103) 179; (107) 23; (111) 7
Human skin fibroblast; (110) 277
Human stratum corneum; (103) 163; (104) 61
Humidity effect; (108) 195
Hyaluronate benzyl ester; (111) 295
Hyaluronic acid; (111) 205; (111) 295
Hyaluronic acid benzyl ester; (107) 91
Hydrate; (108) 195
Hydration; (110) 147; (112) 1
Hydration properties; (112) 29
Hydrochlorothiazide; (107) 141; (108) 207; (110) 249
Hydrochlorothiazide capsule; (110) 257
Hydrocolloid dressing; (112) 29
Hydrocortisone; (103) 93; (106) 7; (110) 211
Hydrocortisone 21-acetate; (110) 231
Hydrocortisone sodium phosphate; (106) 7
Hydrocortisone sodium succinate; (106) 7
Hydrogel; (104) 107
Hydrogen bond; (104) 125

Hydrogen peroxide; (107) 199
Hydrolysis; (101) 145; (104) 29; (106) 7; (106) 135; (107) 67
Hydrolysis kinetics; (105) 147
Hydroperoxy radical; (104) 247
Hydrophile-lipophile balance; (103) 267
Hydrophilic drug; (103) R1
Hydrophilicity; (104) 41
Hydrophilic polymer; (105) 65
Hydrophobic drug; (103) R1
Hydrophobic interaction; (108) 69
Hydroxpropylmethylcellulose; (112) 37
Hydroxyapatite; (112) 215
Hydroxyl radical; (104) 247; (107) 199
7-*N*-(*p*-Hydroxyphenyl)mitomycin C; (105) 249
Hydroxypropylated cyclodextrin; (101) 97
Hydroxypropyl-β-cyclodextrin; (106) 63
2-Hydroxypropyl-β-cyclodextrin; (106) 135
Hydroxypropyl-β-cyclodextrin; (108) 69
Hydroxypropyl methylcellulose; (102) 207; (103) 205; (104) 115; (104) 181
Hydroxypropylmethylcellulose; (111) 251
Hydroxypropyl methylcellulose; (112) 191
Hydroxypropylmethylcellulose solution; (109) 115
Hygroscopicity; (105) 209
Hyphal development; (105) 71

Ibuprofen; (106) 25; (107) 179; (112) 37; (112) 233
ICRF-187; (107) 67
Image analysis; (109) 209; (109) 221; (112) 153
Imide; (107) 67
Immunomodulating compound; (105) 235
Inclusion; (106) 63
Inclusion ability; (101) 97
Inclusion complex; (106) 135; (106) 179; (112) 249
Individual particle; (111) 43
Indomethacin; (104) 1; (104) 1; (104) 87; (106) 25; (106) 63; (106) 115
Indomethacin tablet; (112) 87
Inert matrix tablet; (109) 229
Inflamed eye; (110) 211
Infrared spectrocopy; (112) 165
Infrared spectroscopy; (101) 23; (101) 169
Infrared spectrum, Solubility, Stability; (101) 127
Infusion bag; (110) 197
Inhalation; (107) 57
Inhalation therapy; (104) 73
Injectable o/w emulsion; (110) 189
Injection pain; (109) 45
Inlet air temperature; (102) 117
In-line intravenous filter; (103) 87
Instrumentation; (107) 29; (107) 219
Insulin; (101) 191; (105) 219; (111) 213
Insulin degradation; (111) 147
Insulin delivery; (101) 15
Insulin delivery system; (101) 191
Interaction; (101) 227; (102) 167; (102) 207
Interactive mixing; (104) R1; (112) 55
Interfacial cross-linking; (103) 253
Interferon; (101) 63
α-Interferon; (104) 145
Intermanufacturer variability; (103) 9; (107) 247; (109) 1
Intestinal absorption; (108) 39; (109) 197
Intestinal delivery; (112) 207
Intestinal lysosomal proteolytic activity; (107) 133
Intestinal mucosa; (112) 133
Intestinal perfusion; (109) 125
Intestinal ring; (107) 223
Intestinal uptake; (104) 227
Intraduodenal model; (102) 177
Intralipid; (107) 121
Intramolecular aminolysis; (101) 145
Intramolecular rearrangement; (105) 169
Intramuscular administration; (105) 189
Intranasal administration; (110) 93
Intraperitoneal administration; (107) 41
Intraperitoneal chemotherapy; (110) 117
Intraperitoneal injection; (110) 155
Intraperitoneal model; (102) 177
Intraportal model; (102) 177
Intrathecal administration; (107) 41
Intrauterine administration; (111) 197
Intrinsic viscosity; (103) 225
Inverse gas chromatography; (111) 241
In vitro availability; (103) 119
In vitro diffusion; (110) 211
In vitro dissolution; (102) 213
In vitro evaluation; (106) 69
In vitro hemolysis; (101) 97
In vitro-in vivo correlation; (103) 115; (104) 11
In vitro – in vivo correlation; (110) 65
In vitro-in vivo correlation; (111) 181
In vitro membrane diffusion; (111) 1
In vitro permeation; (103) 27; (111) 191
In vitro release; (109) 251
In vitro study; (109) 35
In vivo model; (103) 259
Iodine-polyurethane interaction; (103) 199
Ionic strength effect; (108) 95
Ionization constant; (109) 261
Ionizing radiation; (104) 49
Iontophoresis; (101) 105; (101) 219; (101) R1; (106) 7; (107) 23; (111) 73
Iontophoretic permeation cell; (101) 219
IOP depression; (105) 147
Isopropyl myristate solubility; (111) 223
Isosorbide nitrate; (107) 111
Isothermal microcalorimetry; (105) 125
Itazigrel; (102) 133
Ivermectin; (103) 93

Jet nebulizer; (104) 73

Ketoprofen; (106) 25; (109) 107
Kinetic order; (107) 243; (112) 93

Kinetics; (101) R1; (102) 193; (104) 29

L-649,923; (109) 237
Lactate dehydrogenase; (104) 73; (109) 17
Lactose; (102) 1; (110) 203; (110) 249; (110) 257
Lag time; (110) 1
Lag time method; (109) 283
Langmuir film; (108) 109
Langmuir isotherm; (108) 31
Large intestine; (110) 47
Laser Doppler velocimetry; (111) 111
Latex; (101) 257; (103) 47
LDL receptor; (110) 277
Leachable; (108) 1
Lecithin purity; (106) 51
Leukemic T-cell; (111) 25
Leukocyte elastase; (104) 151
Leukotriene biosynthesis inhibitor; (103) 259
Leukotriene D_4 antagonist; (109) 237
Leuprolide; (108) 49
Leuprolide aerosol; (107) 57
Leutininzing hormone releasing hormone; (105) 7
LHRH; (105) 241
LHRH agonist; (108) 49
LH-RH analog; (107) 57
Light scattering; (105) 235
Light stability; (103) 69
d-Limonene; (103) 179
d-Limonene; (105) 31
Lipid A subunit analog; (111) 15
Lipid composition; (103) 81
Lipidic amino acid; (102) 223; (105) 241; (106) 85
Lipidic peptide; (102) 223; (105) 241; (106) 85
Lipid mixing; (105) 259
Lipid phase transition temperature; (102) 25
Lipofundin MCT/LCT; (101) 175
Lipofundin MCT/LCT; (107) 121
Lipophilic derivative; (109) 73
Lipophilicity; (102) 231; (112) 181
Lipophilic prodrug; (110) 189
Liposomal stability; (112) 249
Liposome; (101) 227; (102) 25; (102) 151; (102) 159; (103) 81; (103) 131; (103) 237; (103) 277; (103) R1; (107) 1; (107) 99; (107) 149; (107) 189; (110) 161; (111) 15; (111) 103; (112) 249
Liposome-entrapped methotrexate; (108) 21
Liposphere; (105) R1
Liquid crystalline phase; (108) 195
Liquid crystalline system; (111) 283
Lisinopril; (107) 77
Lithium dodecyl sulfate; (110) 267
Liver non-parenchymal cell; (105) 19
LL-D49194α_1; (112) 97
Low-density lipoprotein; (110) 277
Lower critical relative humidity; (108) 213
Lubrication; (102) 81
Lung; (101) 81; (104) 151
Lung deposition; (102) 11
Lung function testing; (107) 211
Lymph; (108) 85
Lymphatic transport; (108) 85; (110) 155
Lymph level; (110) 155
Lyoavailability; (106) 109
Lyophilization; (111) 205
Lyotropic liquid crystalline phase; (102) 91; (103) 225
Lysine salt; (105) 209
Lysis; (110) 161

M1; (103) 147
M2; (103) 147
M3; (103) 147
M4; (103) 147
M1; (109) 181
M2; (109) 181
M3; (109) 181
M4; (109) 181
Macromolecular prodrug; (105) 57
Macromolecular size; (105) 235
Macromolecule; (102) 19
Macrophage; (107) 189
Magnesium stearate; (110) 249
Malaria chemotherapy; (110) 189
Mannitol; (107) 199
Matrix; (101) 23; (110) 285
Matrix carrier; (112) 125
Matrix tablet; (105) 65; (111) 251
MCC; (109) 209
Mean yield pressure; (112) 225
Mebendazole; (102) 231; (104) 175
Mechanical activation; (111) 159
Mechanical properties; (103) 293; (109) 9; (112) 191
Mechanical testing; (104) 203
Mechanism; (104) 29
Mechanism α; (109) 59
Mechanism β; (109) 59
Medium chain triglyceride; (101) 175
Medium chain triglyceride (MCT); (107) 121
Mefloquine; (110) 189
Mefloquine hydrochloride; (101) 127
Melanotropin (6–9); (101) 57; (103) 77; (107) 23
α-Melanotropin; (102) 193
Melting point; (112) 1
Melting temperature-membrane transport; (104) 19
Membrane; (103) 217
Membrane fusion; (107) 99
Membrane permeability; (105) 137; (109) 147; (111) 31
Mesenteric lymph; (102) 261
Mesna; (104) 151
Metabolism; (112) 181
Metal-ion complexation; (106) 229
Metastable amylose; (102) 81
Metered dose inhaler; (101) 81; (106) 69
Methacrylate polymer; (111) 127
Methocel; (109) 91

Method development; (103) 187
Method validation; (103) 187
Methotrexate; (102) 35; (105) 83; (106) 221; (108) 21; (111) 25
Methotrexate-bearing negatively charged liposomes; (102) 35
Methotrexate dialkyl ester; (102) 241; (107) 9
Methoxy/hydropropoxy substitution; (103) 205; (104) 115
8-Methoxypsoralen; (110) 65
Methyl phosphonate oligonucleotide; (107) 169
Methylprednisolone; (110) 9
Metoclopramide; (104) 107
Metronidazole; (109) 251
Micellar; (102) 109
Micellar solubilization; (101) 209; (107) 159
Micelle; (105) 137
Micelle solubilization; (109) 197
Microbial azo reduction; (106) 255
Microcalorimetric titration; (104) 239
Microcalorimetry; (104) 135; (104) 239
Microcapsule; (103) 253; (106) 25
Microcapsules; (109) 271
Microcrystalline cellulose; (101) 169; (108) 31; (110) 203; (111) 43; (112) 225
Microemulsion; (105) 77; (105) R1; (111) 63; (111) 235
Microemulsions; (106) 51
Microindentation; (106) 187
Microparticle; (106) 77
Microparticles; (103) 37
Microscopy; (105) 39
Microsphere; (103) 119; (103) 267; (106) 213; (107) 41; (107) 205; (110) 117; (111) 217
Microsphere absorption; (102) 261
Microspheres; (102) 101
Milling; (101) 237
Mitomycin derivative; (105) 249
Mitoxantrone; (103) 81; (107) 149
Mitozantrone; (103) 87
Mixed micelle; (109) 147
Mixed micelles; (107) 159
Mixed solvent system; (109) 291
Mixer torque rheometry; (102) 167
MK-886; (103) 259
Mobile order theory; (101) 199; (104) 125
Modelling; (105) 103
Moisture content; (102) 81
Moisture permeability; (112) 191
Moisture sorption; (103) 103; (104) 135
Moisture sorption analysis; (103) 205
Moisturiser; (105) 103
Molar heat of solution; (111) 159
Molecular modeling; (106) 179
Molecular rearrangement; (109) 59
Molecular size; (103) 205; (104) 115
Molecular weight; (107) 23; (112) 191
Monkey skin; (110) 137
Monocarboxylic acid; (108) 225
Monoester stability; (102) 241
Monoglyceride; (104) 1; (104) 87
Monoglyceride liquid crystal; (111) 283
Monolayer; (107) 239
Morphine hydrochloride; (101) 219
α-MSH(6–9); (101) 57
Mucoadhesion; (107) 91
Mucosal barrier recovery; (101) 15
Multidrug resistance; (102) 55
Multilayer feedforward network; (108) 155; (110) 101
Multilinear stepwise regression; (102) 117
Multilinear stepwise regression analysis; (108) 155; (110) 101
Multiple emulsion; (111) 137
Multiple-unit dosage form; (111) 181
Multistage liquid impinger; (103) 119
Multivariate calibration; (106) 141
Murine peritoneal macrophage; (107) 149
Myeloperoxidase-H_2O_2 system; (104) 151

Nafarelin acetate; (110) 137
Nanocapsule; (103) 283
Nanoparticle; (103) 283; (106) 201; (111) 31
Nanoparticles; (101) 165; (110) 21
Naproxen; (106) 179
Nasal; (105) 7; (107) 231
Nasal absorption; (103) 27; (110) 93
Nasal delivery; (112) 181
Nasal mucosa; (103) 27
Nebulisation; (103) 119
Nebuliser; (102) 159
Neonatal rat skin; (108) 141
Net work; (112) 173
Neural computing; (108) 155
Neurocomputing; (110) 101
Neurotensin; (112) 133
Neutron activation; (102) 101
Neutrophil; (104) 151
Nifedipine; (103) 69; (103) 179; (108) 11; (111) 235
Niosome; (108) 117
Niosomes; (105) 1
Nitroglycerin; (110) 197
NMR; (102) 109; (109) 99; (110) 55
^{1}H-NMR; (106) 179
Nonaqueous solvent; (108) 49
Non-enzymatic conversion; (112) 143
Nonionic surfactant; (105) 77; (106) 15; (110) 47; (110) 155
Non-ionic surfactant vesicle; (108) 117
Nonlinear regression; (107) 243; (112) 93
Non-linear three-element mechanical model; (106) 187
Nontoxic penetration enhancer; (111) 191
Nordazepam; (106) 109
Normal eye; (110) 211
NSAID; (108) 109
Numerical convolution; (104) 215
Numerical model; (102) 47
Nystatin; (101) 121

Octyl methoxycinnamate; (108) 57
Ocular delivery; (105) 147

Ocular drug delivery system; (103) 283
Ofloxacin; (106) 229
Oleic acid; (101) 57; (103) 77; (105) 47
Ophthalmics; (106) 161
Ophthalmic sustained release; (111) 295
Ophthalmology; (110) 211
Optical rotation enhancement; (108) 95
Optimization; (109) 135; (111) 89
Oral absorption; (102) 177; (102) 223; (105) 235
Oral administration; (102) 47; (106) 201
Oral availability; (101) 89; (110) 47
Oral bioavailability; (103) 259
Oral drug delivery; (104) 227; (107) 223; (110) 127
Oral drug delivery system; (111) 271; (112) 241
Oral immunization; (108) 133; (111) 137
Oral time-based system; (108) 77
Ordered mixing; (112) 55
Organ distribution; (105) 157
Organic acid; (101) 89; (110) 47
o/w emulsion; (109) 251
Oxidation; (110) 241; (111) 153
Oxidative stress; (110) 161
Oxprenolol hydrochloride; (112) 93

P388; (102) 55
Packability; (105) 11
Paddle dissolution method; (112) 233
P388/ADR; (102) 55
Pain assessment; (109) 45
Paracetamol; (102) 71; (104) 215; (112) 241
Paracetamol crystal; (112) 17
Parallel/sequential metabolic scheme; (107) 9
Parenteral dosage form; (102) 63
Parenteral feeding mixture; (101) 175; (107) 121
Partial coating; (112) 47
Partial molar enthalpy; (104) 239
Particle; (108) 233
Particle adhesion; (104) R1; (112) 55
Particle deposition; (106) 69
Particle shape; (111) 43
Particle size; (101) 169; (103) 9; (103) 137; (103) 205; (103) 277; (104) 115; (104) 271; (107) 205; (107) 211; (108) 233; (109) 135; (111) 43; (112) 65
Particle size analysis; (109) 1
Particle size distribution; (110) 37
Particle size effect; (106) 33
Particle surface; (111) 43
Particle surface structure; (111) 159
Particle uptake; (105) 157
Particulate matter contamination; (103) 125
Partition coefficient; (101) 145; (107) 23; (108) 173; (111) 223; (112) 1
Partitioning; (106) 115; (111) 1
P388 cell; (101) 97
PCR-generated DNA fragment; (105) 181
Pectic acid; (109) 271
PEG-40 hydrogenated castor oil; (108) 207
Pellet; (103) 55; (108) 207; (109) 209; (109) 221; (111) 89
Pellet quality; (107) 29
Penetration; (102) 151
Penetration enhancer; (101) 57; (102) 19; (103) 77; (104) 61; (110) 137; (111) 73; (111) 235
Pepsin; (101) 165
Peptidase; (105) 7
Peptide; (102) 193; (104) 145; (104) 187; (106) 95; (107) 57; (111) 197
Peptide drug delivery; (107) 57
Peptide transport; (111) 213
Peptide transporter; (104) 187
Percent crystallinity; (101) 237
Percent recovery; (102) 185
Percolation theory; (101) 45; (109) 229
Percolation threshold; (109) 229
Percoll™; (105) 39
Percutaneous absorption; (102) 19; (102) 141; (105) 31; (106) 1; (109) 251; (110) 137; (110) 231
Percutaneous penetration; (111) 7
Percutaneous permeation; (109) 283
Perfluoroalkylated telomeric surfactant; (104) 41
Peritoneal macrophage; (104) 41
Permeability; (101) 57; (101) 105; (103) 77; (104) 95; (104) 181; (109) 9; (109) 125; (111) 7; (111) 127
Permeability coefficient; (103) 27; (103) 163
Permeation; (101) 15; (105) 219; (107) 231
Permeation enhancer; (101) 15; (109) 283
pH; (102) 201; (106) 125; (109) 91; (111) 261
pH dependence; (112) 143
pH effect; (108) 95
pH equation; (109) 27
pH stability; (101) 219
Phagocytosis; (104) 41
Pharmaceutical dosage form; (111) 83
Pharmaceutical form; (102) 271
Pharmacodynamics; (111) 197
Pharmacokinetic analysis; (105) 19; (108) 125
Pharmacokinetic model; (102) 141
Pharmacokinetic parameters; (109) 107
Pharmacokinetics; (102) 35; (102) 141; (102) 249; (102) 267; (103) 115; (103) 147; (104) 145; (106) 95; (108) 21; (109) 181
Pharmacokinetic simulation; (104) 253
Phase behavior; (106) 51; (111) 63
Phase diagram; (102) 91; (103) 225; (106) 51; (111) 63
Phase separation; (104) 95
Phenol; (112) 143
Phenytoin; (102) 109; (102) 267; (109) 27
Phosphatidylcholine; (103) 217; (105) 259
Phosphatidylethanolamine; (105) 259
Phospholipid; (106) 89; (107) 239
Phospholipid monolayer; (108) 109
Phosphonoformate; (104) 157; (108) 225
Photodecomposition; (103) 69
Photodegradation; (110) 55
Photoisomerization; (110) 55
Photolytic degradation; (103) 69

Photoproduct; (110) 55
Photoprotection; (103) 69
Photostability; (107) 199
Photostabilization; (103) 69
pH-rate profile; (109) 261
pH-sensitive liposomes; (101) 191
pH-solubility profile; (108) 173
Physical form; (110) 9
Physical properties; (106) 103; (112) 125
Physical restriction; (112) 47
Physical scraping; (102) 241
Physicochemical properties; (108) 233
Physostigmine; (109) 283
Piroxicam; (106) 1; (111) 1
Plastic deformation; (101) 71; (102) 81
Plasticizer; (102) 207; (103) 47; (104) 203; (111) 127; (112) 191
Plasticizer permanence; (103) 293
Pluronic; (112) 79
Podophyllotoxin; (109) 73
Poisson's ratio; (105) 177
Polarity; (102) 167
Polarized light microscopy; (110) 75
Polarizing microscope; (102) 91
Polarography; (106) 255
Poloxamer 407; (107) 85; (112) 65; (112) 79
Polyalkylcyanoacrylate; (110) 21
Polyalkylcyanocrylate nanoparticles; (102) 55
Polybutylcyanoacrylate; (101) 165
Polybutylcyanoacrylate nanoparticle; (103) 303
Polycarbophil; (112) 87
Poly-DL-lactide; (103) 217
Poly(DL-lactide-co-glycolide); (106) 201
Poly(ε-caprolactone); (103) 283
Polyethylcyanoacrylate; (111) 31
Polyethylene glycol 6000; (102) 207; (108) 207
Polyethylene glycol 4000; (109) 147
Polyethylene glycol 6000; (110) 223; (110) 267
Polyglycolyzed glyceride; (106) 15
Polylactide; (107) 41
Poly(lactide-co-glycolide); (103) 37
Polylactide-co-glycolide; (107) 41
Poly(lactide-co-glycolide); (108) 133; (111) 137
Polymer; (102) 47; (110) 169
Polymer degradation; (103) 37
Polymer film; (104) 203
Polymeric container; (108) 1
Polymeric drug carrier; (104) 227
Polymerization; (106) 249
Polymer-plasticizer interaction; (103) 293
Polymer swelling; (111) 127
Poly(methylmethacrylate) nanoparticles; (110) 29
Polymorphism; (110) 75; (112) 165
Polymorphism, Pseudopolymorphism; (101) 127
Polymyxin B; (102) 201
α,β-Poly(*N*-hydroxyethyl)-DL-aspartamide (PHEA); (105) 57
Poly(*N*-vinylpyrrolidone-co-maleic acid); (104) 227
Polypeptide; (105) 113
Polyplasdone XL®; (110) 257
Polysaccharide; (112) 125
Polystyrene microsphere; (104) 41
Polystyrene sulfonate; (105) 113
Poly(vinyl alcohol); (102) 207
Polyvinylpyrrolidone; (104) 169; (110) 223
Poorly water-soluble drug; (106) 25
Porcine cornea; (110) 211
Pore pathway; (107) 23
Pore size; (105) 113
Pore size distribution; (108) 167
Porosity; (101) 35; (101) 45; (101) 71; (102) 1; (104) 95; (109) 209
Porous cellulose bead; (112) 153
Porous compacted specimen; (105) 177
Porous crystalline cellulose; (108) 167
Porous film; (104) 95
Post-compaction tensile strength increase; (109) 59
Post-proline cleaving enzyme; (112) 133
Potassium dodecyl sulfate; (110) 267
Powder; (103) 155; (105) 125
Powder inhaler; (102) 127
Powder X-ray diffraction; (109) 83
Power consumption; (107) 29; (107) 219
Power-law parameters; (107) 85
Praziquantel; (103) 237
Prazosin; (105) 169
Precipitation; (109) 27
Preclinical safety; (107) 57
Predictive model; (109) 237
Prednisolone ocular delivery; (111) 295
Preformulation; (102) 63
Preparation; (103) 199
Pressurized suspension; (110) 9
Pre-transition; (110) 179
Pretreatment; (106) 1
Primaquine; (110) 161
Primary culture; (101) 121
Primary immune response; (103) 303
Primojel®; (107) 141
Processing; (105) 125; (106) 33
Process modeling; (110) 101
Process modelling; (108) 155
Process variables; (107) 205
Prodrug; (102) 109; (102) 231; (103) 1; (104) 157; (104) 175; (105) 147; (105) 169; (109) 73; (111) 223; (112) 143
Proliferation assay; (101) 121
Prolonged circulation; (111) 103
Prolonged release; (107) 179; (111) 171
Prolylcarboxypeptidase; (107) 133
Propellant; (110) 9
Propranolol; (101) 145; (104) 19; (109) 283; (110) 291
Propranolol ester; (101) 145
Propranolol hydrochloride; (111) 251
(*R,S*)-Propranolol hydrochloride; (109) 83
Propylene glycol; (111) 1
Prostaglandin A_2; (106) 135; (106) 167

Prostaglandin B_2; (106) 135; (106) 167
Prostaglandin E_2; (106) 135; (106) 167
Protein; (101) 63; (109) 17
α_1-Proteinase inhibitor; (104) 151
Protein binding; (108) 241
Proteolysis; (104) 151; (111) 147
Proteolytic degradation; (112) 133
Pseudoephedrine; (111) 171
Pseudo-first order kinetics; (102) 241
Pseudolatex; (104) 203
Pseudomonas aeruginosa; (101) R7
Psoriasis; (105) 227
Pulmonary administration; (106) 95
Pulmonary clearance; (102) 159
Pulmonary delivery; (103) 119
Pulmonary deposition; (102) 159
Pulsed current; (101) 219
Pump reservoir; (101) 257
Punch velocity; (103) 55
PVC; (101) 257
PVC bag; (105) 89
PVC infusion bag; (105) 83
Pyrazole formation; (108) 95

Quantum-chemical calculations; (110) 109
Quinolone; (106) 229
Quinolone determination; (111) 83

Rabbit; (106) 161
Rabbit test; (105) 147
Radiation; (105) 255
Radical; (107) 67
Radiolabeled TOF; (102) 249
Radiolabelled blastospore; (105) 39
Radiolabelled drug; (102) 11
Radiosensitizer; (102) 63
Rapidly soluble dosage form; (101) 63
Rat; (101) 89; (102) 141; (102) 257; (102) 261; (102) 267; (109) 125; (110) 47; (110) 155
Rat skin; (103) 179
Razoxane; (107) 67
Reactive dimension; (108) 187
Recombinant human granulocyte colony-stimulating factor (rhG-CSF); (101) 89
Recombinant human granulocyte colony-stimulatiug factor (rhG-CSF); (110) 47
Recompression; (112) 225
Rectal solution; (104) 215
Red blood cell; (110) 161
Regional oral absorption; (109) 125
Relative diffusivity; (112) 117
Relative lipophilicity; (105) 147
Release; (103) 81; (104) 181; (111) 31
Release curve; (112) 105; (112) 117
Released amount; (106) 1
Release kinetics; (110) 285; (111) 137
Release mechanism; (109) 229; (111) 217
Release medium; (112) 241
Release rate; (102) 19; (105) 1; (106) 149; (108) 117
Renin inhibitor; (102) 177
Renkin factor; (107) 23
Reservoir; (101) 105
Resistance reversion; (102) 55
Resonance energy transfer; (107) 99
Respiratory tract; (101) 1; (112) 181
all-*trans*-Retinoic acid; (111) 111
Reversed-phase HPLC; (102) 271
RGD; (106) 95
Rheological properties; (107) 85
Rheological testing; (109) 115
Rheology; (103) 155; (106) 103; (110) 37; (111) 205
Rifampicin; (108) 125
Rosette-forming cell; (103) 303
Rotational rheology; (107) 51
RS-1541; (110) 277
RS-1541/LDL complex; (110) 277
RU 41740; (105) 235
Rubber stopper; (103) 125

Salbutamol; (107) 211
Salbutamol sulfate; (108) 233; (111) 241
Salt form selection; (109) 237
Salt selection; (105) 209
Sample weight effect; (106) 33
Saturated fatty acid triglyceride; (110) 155
Scanning electron microscopy; (102) 81; (109) 221; (111) 117
Scavenger receptor; (105) 19
Schistosomiasis; (103) 237
Scleroglucan; (112) 125
Secondary structure; (108) 49
Second-order derivative UV spectrophotometry; (108) 11
Second-order kinetics; (106) 25
Seeded crystal growth; (112) 215
Selective catheterism; (106) 41
Self-emulsification; (106) 15
Semisolid emulsion system; (107) 51
Semi-solid lipid matrices; (110) 65
Serum; (101) 97
Serum G-CSF concentration; (110) 93
Shear cell; (103) 155
Shear deformation; (106) 125; (111) 261
Shear modulus; (105) 177
Shelf-life; (107) 243; (112) 93
Shell dosage form; (102) 47
Side effects; (104) 87
Silastic®; (111) 1
Silicone surfactant; (107) 51
Simultaneous determination; (108) 11
Simultaneous diffusion/bioconversion; (107) 9
Site-specific oral absorption; (109) 125
Size; (103) 267; (107) 189; (112) 79
Size and shape descriptors; (108) 187
Size distribution; (111) 15
SK&F 106760; (106) 95

Skin; (102) 151; (103) 131; (104) 19; (109) 283
Skin flux; (110) 137
Skin hydration; (105) 103
Skin irritation; (111) 111
Skin metabolism; (110) 137
Skin permeability; (103) 163; (105) 103; (107) 23
Skin permeation; (111) 191
Skin retention; (110) 231
Slugging; (112) 225
Small intestine; (107) 223; (110) 127
Small intestine transit time; (108) 77
Sodium alginate; (107) 179; (111) 171
Sodium carboxymethylcellulose; (106) 103; (110) 285
Sodium cholate; (109) 147
Sodium cromoglycate; (102) 127
Sodium dodecyl sulfate; (105) 137; (110) 267
Sodium glycocholate; (111) 213
Sodium hyaluronate; (106) 161
Sodium lauryl sulfate; (107) 239; (110) 147; (111) 73
Softbag; (110) 197
Solid bridge stabilization; (109) 59
Solid bridging; (104) R1; (112) 55
Solid complex; (109) 99
Solid dispersion; (103) 137; (104) 169; (106) 109; (108) 101
Solid solution; (110) 267
Solid-state NMR; (110) 267; (111) 43
Solubility; (101) 199; (102) 133; (102) 231; (104) 181; (105) 137; (109) 27; (109) 147; (110) 9; (110) 137; (111) 159; (112) 1; (112) 165
Solubility data linearization; (109) 291
Solubility estimation; (109) 291
Solubility parameters; (111) 223
Solubility prediction; (104) 125; (108) 149
Solubilization; (105) 77; (110) 169
Solute-solvent complexation; (101) 199
Solution calorimetry; (112) 65
Solution kinetics; (111) 153
Solvent effect; (104) 125
Solvent evaporation method; (106) 213
Solvent evaporation process; (106) 201; (109) 271
Sorbed moisture content; (104) 115
Sorbitan ester; (105) 1; (108) 117
Sorbitol; (107) 199
Sorivudine; (103) 69
Sorivudine (BV-araU); (110) 249
Sorption; (101) 23; (110) 197
Sotalol; (105) 65
Soybean lecithin; (106) 51; (111) 63
Spacer device; (106) 69
Sparingly soluble salt; (109) 271
Specific surface; (107) 247
Specific surface area; (108) 167
Spectrophotometry; (110) 197
Spectroscopy; (105) 47
Spherical agglomeration; (101) 63
Spherical crystallization technique; (105) 11
Spherical matrix; (112) 153
Spheronisation; (107) 29
Spheronization; (111) 89
Spinning top generator; (107) 211
Spiramycin; (110) 223
Spray-dried lactose; (112) 225
Spray drying; (108) 233
Spreading; (102) 167
SQ-33600; (108) 195
Stability; (101) 145; (101) 165; (101) 257; (102) 35; (102) 63; (102) 193; (103) 147; (105) 147; (105) 169; (106) 7; (106) 135; (107) 1; (107) 111; (107) 141; (107) 243; (109) 17; (109) 261; (111) 51; (112) 93; (112) 143
Stability constant; (104) 125
Stability indicating assay; (102) 201
Stability kinetics; (106) 167
Stability profile; (109) 191
Stagnant diffusion layer; (101) 209; (107) 159
Starch capsule; (112) 207
Steady state; (109) 283
Stearic acid; (112) 165
Steroid; (103) 19
Stirring rate; (103) 137
Stokes-Einstein radius; (105) 113
Stomach; (109) 91
Storage; (103) 93; (105) 83
Storage effect; (108) 213
Stratum corneum; (105) 47; (107) 23; (111) 235
Stress relaxation; (106) 187
Stripping; (111) 7
Structure; (110) 267
Structure-activity relationship; (110) 109
Subcutaneous administration; (105) 189
Submicron emulsion; (108) 57
5-Substituted 2-(3-pyridyl)benzoxazoles; (110) 109
Succinylated bovine serum albumin; (105) 19
Succinylated superoxide dismutase; (105) 19
Succinylated uricase; (105) 19
Suckling rat; (108) 39
Sucrose; (107) 199
Sulfamethoxazole; (110) 55
Sulfide-dicarboxylic acid; (111) 153
Supercritical fluid extraction; (106) 77
Supercritical gas; (106) 77
Superdisintegrant; (110) 257
Supersaturation; (111) 1
Suppository; (102) 213; (104) 87; (104) 215; (112) 233
Surface-active agent; (110) 223
Surface adsorption interaction; (108) 31
Surface area; (101) 71; (108) 213
Surface charge; (107) 189
Surface energy; (102) 167
Surface free energy; (111) 241
Surface geometry; (108) 187
Surface mobility; (104) 41
Surface molecule rearrangement; (111) 159
Surface pressure; (107) 239
Surface properties; (105) 125; (111) 241

Surfactant; (101) 209; (102) 257; (103) 119; (105) 219; (107) 159; (108) 141; (109) 197; (110) 9; (110) 179
Surfactant adsorption; (103) 19
Surfactant type; (103) 267
Suspension; (101) 263; (109) 271
Sustained release; (106) 213; (109) 271
Sustained-release dosage form; (111) 181
Swellable system; (112) 47
Swelling; (104) 107; (112) 47
Swelling force; (112) 29
Synchrotron radiation; (103) 225
Synthetic iron oxide; (103) 69
Synthetic membrane; (105) 113
Synthetic oligonucleotide; (105) 181

Tablet; (101) 71; (106) 149; (111) 51
Tablet coating; (102) 207
Tableting excipient; (105) 255
Tableting parameters; (105) 255
Tableting properties; (110) 37
Tablet properties; (102) 117
Tablet tensile strength; (108) 213
Tabletting; (112) 37
Tape-stripped skin; (107) 9
Targeting; (103) 237
Taurocholate; (109) 197
Tautomerism; (110) 55
^{99m}Tc; (102) 159
Temperature; (102) 201
Temperature effect; (105) 31; (108) 95
Teniposide; (105) 89
Tensile force measurement; (107) 91
Tensile strength; (103) 55; (104) 115; (110) 75; (111) 51
Terbutaline sulfate; (106) 213
Terephthaloyl chloride; (103) 253
Tetrahydroaminoacridine; (109) 283
Tetrandrine; (109) 135
Tetrapeptide; (101) 57; (103) 77; (107) 23
Theophyline; (108) 149
Theophylline; (103) 115; (106) 149; (111) 271; (112) 241
Theophylline monohydrate; (106) 33
Thermal analysis; (101) 127
Thermal gelation; (107) 85
Thermal stability; (111) 223
Thoracic lymph duct; (110) 155
Thymidylate synthase inhibitor; (105) 227
Thyrotropin-releasing hormone; (107) 231
Time-controlled explosion system (TES); (110) 1
Timed release; (111) 99
Tissue distribution; (102) 35; (102) 249; (106) 201; (108) 21; (109) 181
Titanium dioxide; (105) 157
TNF induction; (111) 15
Tobramycin; (108) 39
α-Tocopherol; (104) 49; (111) 261
Tolerance; (106) 161
Tolmetin; (103) 217
Tomato lectin; (107) 223; (110) 127
Topical application; (102) 151
Topical delivery; (103) 131; (103) 277; (103) R1
Topical formulation; (103) 187; (104) 181; (105) 227
Total parenteral nutrition; (101) 175; (107) 121
Training end point; (110) 101
Transdermal; (104) 19
Transdermal delivery; (103) 131; (106) 7; (108) 141; (111) 223
Transdermal drug delivery; (111) 73
Transdermal penetration; (103) 179
Transendometrium; (111) 197
Transmission electron microscopy; (107) 51
Tretinoin; (106) 125; (110) 241; (111) 111
TRH; (105) 241
Triamcinolone acetonide; (109) 283
Triglyceride; (111) 51
Trinitrobenzenesulfonic acid; (103) 253
Tritiated water flux; (101) 219
Triton X-100; (103) 19
Tropical conditions; (109) 9
[D-Trp-6]LHRH; (105) R1
Trypsin; (102) 241
Trypsin inhibitor; (101) 89
Twin Impinger; (106) 69
Tyloxapol; (102) 91; (103) 225
Tyrphostin; (104) 29

Ultrafiltration; (109) 99
Ultrasonic nebuliser; (103) 119
Unit cell dimensions; (109) 83
Uracil; (103) 93
Urea bead; (112) 117
Urine; (111) 83
Ursodeoxycholic acid; (109) 173
Ussing chamber; (106) 237; (107) 231

Vaginal tissue; (106) 237
Validation; (106) 141
Valve; (106) 69
Vancomycin; (109) 261
V3 BRU peptide; (111) 137
Vehicle effect; (111) 1
Verapamil; (102) 267
Vesicle morphology; (105) 259
Viability; (106) 237
Vinblastine sulfate; (103) 87
Vincristine; (111) 25
Vincristine sulfate; (103) 87
Visco-elastic deformation; (109) 59
Viscoelasticity; (107) 51
Viscosity; (106) 1; (111) 251
Viscosity grade; (112) 173

Warfarin sodium; (110) 197
Water loss; (110) 147
Water solubility; (111) 223
Water sorption; (101) 237

Water uptake; (112) 29
Water vapor adsorption; (108) 167
Water vapor diffusion; (101) 35
Weak electrolyte; (109) 191
Weaning period; (108) 39
Wet granulation; (102) 167
Wetting; (102) 167
Wilhelmy plate; (109) 155
w/o emulsion; (109) 251
Work hardening; (112) 225
Work of compaction; (103) 55
w/o/w emulsion; (109) 251

X-ray analysis; (104) 135
X-ray behavior; (107) 85
X-ray diffraction; (101) 23; (101) 169
X-ray diffractometry; (108) 101
X-ray powder diffraction; (101) 237; (110) 267; (112) 165
X-ray powder diffractometry; (101) 127
X-ray scattering; (103) 225

Young's modulus; (105) 177

Zanasi AZ5; (110) 249
Zero-order absorption process; (102) 141
Zero-order period; (109) 229
Zero-order release; (112) 37
Zeta potential; (101) 227; (104) 41; (108) 57
Zeta-potential; (111) 15
Zinc-aspirin complex; (108) 173
Zinc sulfate; (104) 247; (108) 173